Home
  >  
Section 35

EurekaMag Full Text Articles Chapter 34,778



References:

Bessone, S.; Vidal, F.; L.B.uc, Y.; Epelbaum, J.; Bluet Pajot, M.T.erese; Darmon, M. 1999: EMK protein kinase-null mice Dwarfism and hypofertility associated with alterations in the somatotrope and prolactin pathways. Developmental Biology. 214(1): 87-101,. 1
Kergoat, M.; Arbellot, A.; Audet, A.; Moinet, G.; Durbin, P.; Autier, V. 2003: EML 257 A promising new oral antidiabetic compound with a dual action to address insulin secretion and insulin action defects. Diabetes 52(Suppl 1): A123
Kergoat, M.; Bailbe, D.; Autier, V.; Arbellot, A.; Moinet, G.; Durbin, P.; Portha, B. 2003: EML 257 restores a glucose-dependent effect on pancreatic hormonal secretion in rat models of type 2-diabetes. Diabetologia 46(Suppl 2): A 300
Bolze, S.; Vigie, A.; Huber, F.; Ladstetter, B. 2003: EML 257, a promising new oral antidiabetic compound with a favourable pharmacokinetic profile. Diabetes and Metabolism 29(Hors serie 2): 4S266
Martinez Rubio, D.R.; Soto, A.G.; Oliveira, F.; Lopez, F.; Sola, A. 2000: EMLA cream for percutaneous venous central line placement in preterm infants A randomized, controlled trial. Pediatric Research 47(4 Part 2): 415A
Krief, W.; Sadock, V.; Tunik, M.; Mojica, M.; Manikian, A. 2002: EMLA versus LET for topical anesthesia in wound repair. Pediatric Research 51(4 Part 2): 43A
Hahn, I.; Hoffman, R.S.; Nelson, L.S. 1999: EMLA-induced methemoglobinemia and lidocaine toxicity. Journal of Toxicology. Clinical Toxicology 37(5): 621
Major, T.C.; Lu, X.; Dagle, C.; Bocan, T.M.A. 2000: EMMPRIN , a human tumor cell-derived protein, is induced upon monocyte differentiation and is expressed in human atheroma. Circulation 102(18): 2; 39
Lu, X.; Major, T.C.; Bocan, T.M.A. 2001: EMMPRIN is expressed in atherosclerotic lesions of apolipoprotein E-deficient mice. FASEB Journal 15(4): A211
Stacey, M.; Chang, G.W.; Sanos, S.; Chittenden, L.; Stubbs, L.; Gordon, S.; Lin, H.H. 2002: EMR4, a novel EGF-TM7 molecule up-regulated in activated mouse macrophages, is involved in the adhesion to a B lymphoma cell line, A20. Biochemical Society Transactions 30(3): A86
Johns, C.S.; Chamberlain, J.M.; Teach, S.J.; Wright, J.L. 2000: EMS provider training and experience with pediatric death. Pediatric Research 47(4 Part 2): 110A
Aizencang, G.I.; Bishop, D.F.; Astrin, K.H.; Desnick, R.J. 2000: EMSA studies define a GATA1/CP2 erythroid transcription complex in the uroporphyrinogen III synthase gene. American Journal of Human Genetics 67(4 Suppl 2): 41
Pearson, M.; Barr, T.L. 2003: EMU oil-based formulations for use as an analgesic, anesthetic and antipruritic. Official Gazette of the United States Patent and Trademark Office Patents 1268(1)
Martin, N.L.; Sauvageau, G. 2003: EN2 is an oncogene involved in human breast cancer. Proceedings of the American Association for Cancer Research 44: 179
Reichlin, M. 2002: ENA: its place in medicine. Lupus 11(4): 201-203
Thomas, R.A.; Mcfarland, D.; Tierney, L.A.; Narayanan, P.K.; Schwartz, L.W. 2004: ENA-78 induced up-regulation of CD11b in whole blood A novel assay for C-X-C chemokine induced neutrophil activation in dogs. Cytometry 59A(1): 131
Saint, F.; Salomon, L.; Cicco, A.; De La Taille, A.; Quintela, R.; Hoznek, A.; Perney, C.; Chopin, D.; Abbou, C.C. 2003: ENDO FMS fluid management Toward a new system to decrease bleeding and to improve surgical procedure during transurethral resection of the bladder and the prostate ?. European Urology Suppls 2(1): 104
Hoffman, B.M.; Davydov, R. 2003: ENDOR characterization of intermediates in the activation of dioxygen by Fe enzymes. Journal of Inorganic Biochemistry 96(1): 148, 15 July
Tierney, D.L.; Martasek, P.; Huang, H.; Doan, P.E.; Masters, B.S.e Siler; Silverman, R.B.; Hoffman, B.M. 1999: ENDOR of NOS Spectroscopic derivation of substrate location and structure. Journal of Inorganic Biochemistry 74(1-4): 314
Poluektov, O.G.; Utschig, L.M.; Dubinskij, A.A.; Thurnauer, M.C. 2004: ENDOR of spin-correlated radical pairs in photosynthesis at high magnetic field: a tool for mapping electron transfer pathways. Journal of the American Chemical Society 126(6): 1644-1645
Tierney, D.L.; Doan, P.E.; Huang, H.; Martasek, P.; Masters, B.S.e Siler; Silverman, R.B.; Hoffman, B.M. 1999: ENDOR spectroscopic determination of the position and structure of enzyme-bound substrates Holo- nitric oxide synthase. Journal of Inorganic Biochemistry 74(1-4): 32
Garcia Cuellar, M.P.; Schreiner, S.A.; Birke, M.; Hamacher, M.; Fey, G.H.; Slany, R.K. 2000: ENL, the MLL fusion partner in t , binds to the c-Abl interactor protein 1 that is fused to MLL in t +. Oncogene 19(14): 1744-1751
Lacy, M.Q.; Dispenzieri, A.; Gertz, M.A.; Witzig, T.E.; Greipp, P.R.; Fonseca, R.; Lust, J.A.; Kumar, S.; Zeldenrust, S.; Kyle, R.A.; Snow, D.; Hayman, S.R. 2003: ENMD-0995 , a novel thalidomide analogue, has promising clinical activity for patients with relapsed refractory multiple myeloma Preliminary results of a Phase I clinical Trial. Blood 102(11): 453a
Foster, C.M.; Graves, W.R.; Hannapel, D.J.; Horner, H.T. 1999: ENOD2 transcript accumulation in indeterminate nodules of the woody legume, Maackia amurensis Rupr Maxim. Plant Biology (Rockville) : 179
Naber, C.; Baumgart, D.; Erbel, R.; Heusch, G.; Siffert, W. 2000: ENOS 894T-allele and coronary vasoconstriction upon alpha2-adrenoceptor activation. FASEB Journal 14(4): A166
Wang, X.; Sun, Z. 2004: ENOS Gene Delivery Attenuates Cold-induced Hypertension. FASEB Journal 18(4-5): Abstract 823
Langston, J.W.; Duranski, M.R.; Turnage, R.H.; Kevil, C.G.; Rogers, H.T.; Champion, H.C.; Lefer, D.J. 2004: ENOS Gene Therapy Protects the Liver Against Ischemia-Repefusion Injury. FASEB Journal 18(4-5): Abstract 441
Imamura, A.; Mizuno, T.; Matsui, H.; Okumura, K. 2002: ENOS and MTHFR gene polymorphisms are associated with endothelial dysfunction in young healthy men. Circulation 106(19): II32
Frangos, J.; L'heureux, N.; Dusserre, N. 2003: ENOS association with PECAM-1 involvement in the regulation of eNOS activity by shear stress. FASEB Journal 17(4-5): Abstract 864
Gu, X.; Samuel, S.; Brooks, S.E.; Caldwell, R.B. 2001: ENOS but not iNOS plays a critical role in the pathogenesis of OIR. IOVS Investigative Ophthalmology and Visual Science 42(4): S88
Sasaki, M.; Jordan, P.; Jenings, M.; Alexander, J. 2002: ENOS deficient mice show exaggerated disease activity in experimental colitis. Free Radical Biology and Medicine 33(Suppl 2): S345
Gu, X.; Caldwell, R.B.; Samuel, S.; Huang, P.L.; Brooks, S.E. 2000: ENOS deletion diminishes oxygen-induced retinopathy. IOVS Investigative Ophthalmology and Visual Science 41(4): S537
Rossi, G.P.; Taddei, S.; Albertin, G.; Virdis, A.; Ghiadoni, L.; Favilla, S.; Sudano, I.; Pessina, A.C.; Salvetti, A. 1999: ENOS exon 7 G/T and ACE D/I gene polymorphisms and endothelial dysfunction in mild-to-moderate essential hypertensive patients. Circulation 100(18): 1; 828
Tsuji, T.; Fujisawa, M.; Inaba, Y.; Okada, H.; Kamidono, S. 2001: ENOS expression and apoptotic changes of testicular germ cells in the obstructive azoospermia models of prepubertal and adult rats. Journal of Urology 165(5 Suppl): 335
Tavakkoly Bazzaz, J.; Boulton, A.J.M.; Pravica, V.; Hutchinson, I.V. 2003: ENOS gene promoter polymorphism in Type 1 diabetes and its microangiopathic complications. Diabetes and Metabolism 29(Hors serie 2): 4S42
Lee, J.S.; Chatterjee, S.; Shah, V. 2003: ENOS gene transfer inhibits hepatic stellate cell proliferation and migration through a cGMP independent, S-nitrosylation dependent mechanism Implications for inhibition of tumor angiogenesis in liver. Hepatology 38(4 Suppl 1): 776A
Hassan, A.; Gormley, K.; O'sullivan, M.; Knight, J.; Sham, P.; Vallance, P.; Bamford, J.; Markus, H. 2004: ENOS haplotypes and risk of cerebral small vessel disease. Journal of Neurology Neurosurgery and Psychiatry 75(3): 521-522
Holt, C.M. 2000: ENOS inhibition of proliferation: a role for p21(Sdi1/Cip1/Waf1) and p27(kip1). Cardiovascular Research 47(4): 640-641
Ritter, O.; Schuh, K.; Neyses, L. 2002: ENOS is a novel target gene of AT2-receptor stimulation in the myocardium. Circulation 106(19): II142
Dimagno, M.; Williams, J.; Owyang, C. 2002: ENOS is protective in the initiation of experimental acute pancreatitis. Gastroenterology 122(4 Suppl 1): A-284
Ruetten, H.; Mueller, S.; Dimmeler, S.; Zeiher, A.M. 1999: ENOS knock out mice are protected from decompensation of pressure-overload hypertrophy. Circulation 100(18): 1; 272
Beierwaltes, W.H. 2003: ENOS mediates vasodilatation but not hypertrophy after unilateral nephrectomy. FASEB Journal 17(4-5): Abstract
Dimagno, M.; Hao, Y.; Tsunoda, Y.; Williams, J.; Owyang, C. 2002: ENOS regulates CCK mediated pancreatic secretion in mice. Gastroenterology 122(4 Suppl 1): A 36
Connelly, L.; Moncada, S.; Hobbs, A. 2002: ENOS regulates lipopolysaccharide-induced iNOS expression in murine macrophages. Nitric Oxide 6(4): 374-375
Rogers, H.T.; Zibari, G.; Turnage, R.M.; Yokoyama, M.; Kawashima, S.; Grisham, M.B.; Hines, I.; Lefer, D.J. 2003: ENOS transgenic mice are protected against liver ischemia-reperfusion injury. FASEB Journal 17(4-5): Abstract 567
Lemmer, B.; Arraj, M.; Thomas, M.; Zuther, P. 2004: ENOS-knock-out mice display a disturbed 24-h rhythm in heart rate but not in blood pressure. American Journal of Hypertension 17(5
Wood, T.E.; Lawrence, D.; Clark, D.A. 2002: ENSO effects on leaf litter nutrient cycling in an old growth wet tropical forest in Costa Rica. Ecological Society of America Annual Meeting Abstracts 87: 301
Wood, T.E.; Lawrence, D.; Clark, D.A. 2001: ENSO effects on litter phosphorus dynamics across three edaphic types in wet tropical forests of northeastern Costa Rica. Ecological Society of America Annual Meeting Abstracts 86: 362
Lahti, M.; Swift, C.; Ross, K. 2003: ENSO event effects on Southern California riparian plant communities. Ecological Society of America Annual Meeting Abstracts 88: 195
Poveda, G.; Graham, N.E.; Epstein, P.R.; Rojas, W.; Velez, I.D.; Quinones, M.L.; Martens, P. 1999: ENSO, malaria and dengue in Colombia. AAAS Annual Meeting and Science Innovation Exposition 165: A 33, 21-26 January
Lenters, J.D. 2000: ENSO-related variations in Great Lakes water levels. IAGLR Conference Program and Abstracts 43: A - 87
Buiter, C.T. 2000: ENT - involvement in vasculitis. Clinical and Experimental Immunology 120(Suppl 1): 25-26
Anonymous 2000: ENT Comparative Audit Meeting, Millennium Meeting, Nottingham, UK, September 8, 2000. Journal of Laryngology and Otology 114(11): 894-902
Fossati, D.; Passaretti, S.; Strada, E.; Frego, R.; Mezzi, G.; Testoni, P.A.berto 2000: ENT disorders caused by GERD Efficacy of treatment with pantoprazole. Gastroenterology 118(4 Suppl 2 Pt 2): AGA A1233
Vaezi, M.F.; Hicks, D.M.; Ours, T.M.; Richter, J.E. 2001: ENT manifestations of GERD A large prospective study assessing treatment outcome and predictors of response. Gastroenterology 120(5 Suppl 1): A 118
Shprintzen, R.J. 1999: ENT manifestations of VCFS. Genetic Counseling 10(1): 103-104
Wong, R.K.; Hanson, D.G.; Waring, P.J.; Shaw, G. 2000: ENT manifestations of gastroesophageal reflux. American Journal of Gastroenterology 95(8 Suppl): S15-S22
Garcia Manteiga, J.M.; Mata, J.F.; Mazo, A.; Casado, F.J.; Felipe, A.; Pastor Anglada, M. 2000: ENT1 nucleoside transporter is involved in gemcitabine cytotoxicity in human tumor pancreatic cell lines. Proceedings of the American Association for Cancer Research 41: 841
Cole, D.N.; Clark, K.B.; Lee, W.R.; Wilson, V.L. 2003: ENU induced mutant germ cell clusters in drosophila melanogaster. Environmental and Molecular Mutagenesis 41(3): 168
Nolan, P.M. 2003: ENU mouse mutagenesis screens An update. Behavioural Pharmacology 14(Suppl 1): S17
Kapfhamer, D.; Leach, G.; Sun, Y.; Valladares, O.; Harder, E.; Veasey, S.C.; Bucan, M. 2002: ENU mutagenesis in the mouse Screen for mutations with anomalies in rest-activity behaviour and sleep. Journal of Sleep Research 11(Suppl 1): 118
Stoica, G. 2002: ENU mutagenesis of rat mammary epithelial cells. Methods in Molecular Biology 188: 291-303
Percec, I.; Plenge, R.; Nadeau, J.; Bartolomei, M.; Willard, H. 1999: ENU mutagenesis screen for dominant mutations of X chromosome inactivation. American Journal of Human Genetics 65(4): A51
Goldsworthy, M.; Toye, A.; Hugill, A.; Cox, R.D. 2000: ENU mutagenesis to generate new models relevant to type II diabetes and cardiovascular disease. Basic Research in Cardiology 95(6): 527
Nakatani, Y.ki; Moody, Robert; Smith, William, C. 1999: ENU-induced mutations affecting tail and notochord morphogenesis in the ascidian Ciona savignyi. Developmental Biology 210(1): 205
Stoica, G. 2002: ENU-induced ovarian cancer. Methods in Molecular Biology 188: 305-314
Ohl, F.; Binder, E.B.; Roedel, A.; Weissenbacher, P.; Keck, M.E. 2003: ENU-mouse mutagenesis screen In search of animal models of psychiatric disorders. Pharmacopsychiatry 36(5): 252
Chalfant, M.L.; Denton, J.S.; Karlson, K.H.; Benos, D.J.; Stanton, B.A. 1999: ENaC activates CFTR chloride currents in Xenopus oocytes. FASEB Journal 13(4 Part 1): A70
Lourdel, S.; Zecevic, M.; Paulais, M.; Feraille, E.; Verrey, F.; Teulon, J.; Doucet, A.; Deschenes, G. 2001: ENaC activation in experimental nephrotic syndrome. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 138A
Zhou, Z.H.; Bubien, J.K. 2001: ENaC and CFTR may play a role in regulated antibody secretion. FASEB Journal 15(4): A501
Hummler, E. 2002: ENaC and lung liquid clearance. Pfluegers Archiv European Journal of Physiology 443(Suppl 1): S385
Edinger, R.S.; Hill, W.G.; Johnson, J.P. 2003: ENaC in lipid rafts in mammalian CCD cells Possible functional significance. Journal of the American Society of Nephrology 14(Abstracts Issue): 37A
Berdiev, B.; Jovov, B.; Tucker, W.; Naren, A.; Fuller, C.; Chapman, E.; Benos, D. 2004: ENaC inter-subunit interaction dependence of the syntaxin 1A effects. FASEB Journal 18(4-5): Abstract 681
Auberson, M.; Hoffmann Pochon, N.; Vandewalle, A.; Kellenberger, S.; Schild, L. 2002: ENaC mutants of the PY motif retain their ability to respond to aldosterone, ADH and insulin. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 277A
Awayda, M.S.; Tobey, N.A.; Reger, R.L.; Orlando, R.C. 2000: ENaC participates in the formation of a non-selective cation channel in rabbit esophageal epithelia. FASEB Journal 14(4): A336
Segal, A.; Ullrich, N.D.; Eggermont, J.; Van Driessche, W.; Weber, W.M. 2002: ENaC promotes expression of CFTR while CFTR does not inhibit ENaC. Pfluegers Archiv European Journal of Physiology 443(Suppl 1): S163
Stanton, B.A.; Coutermarsh, B.; Ji, H.L.; Fuller, C.M.; Benos, D.J. 2003: ENaC regulates CFTR trafficking. FASEB Journal 17(4-5): Abstract 797
Carattino, M.D.; Kleyman, T.R. 2002: ENaC regulation by arachidonic acid. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 278A
Konstas, A.A.; Koch, J.P.; Korbmacher, C. 2001: ENaC stimulates surface expression of ROMK1 in Xenopus laevis oocytes co-expressing CFTR. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 34A
Miller, S.M.; Sha, L.; Ermilov, L.G.; Drummond, H.A.; Welsh, M.J.; Ou, Y.; Farrugia, G.; Szurszewski, J.H. 2001: ENaC subunits are components of the mechanosensor of colonic mechanosensory afferent nerves projecting to prevertebral ganglia. Gastroenterology 120(5 Suppl 1): A 83
Drummond, H.A.; Welsh, M.J.; Abboud, F.M. 2001: ENaC subunits are molecular components of the arterial baroreceptor complex. Annals of the new York Academy of Sciences 940: 42-47
Ji, H.L.; Parker, S.B.; Benos, D.J.; Stanton, B.A. 2000: ENaC-CFTR interaction is independent of surface density of CFTR and cytosolic Na+ loading. FASEB Journal 14(4): A334
Skak Nielsen, T.; Fjording, M.S.; Jensen, L.; Hansen, J.R.; Madsen, M.W.; Ottosen, E.R.; Binderup, L. 2001: EO1428, a potent inhibitor of cytokine secretion, is a new p38 MAP kinase inhibitor with systemic activity. Inflammation Research 50(Suppl 3): S184
Skak Nielsen, T.; Petersen, T.K.; Fullerton, A.; Aaes, H.; Fjording, M.; Hansen, J.R.; Ottosen, E.R.; Madsen, M.W. 2004: EO1606 - a p38 MAP kinase inhibitor as a potential treatment of acne. Journal of Investigative Dermatology 123(2)
Redmond, K. 1999: EONS core curriculum. European Journal of Cancer 35(Suppl 4): S24
Redmond, K. 2001: EONS curriculum for advancing cancer nursing practice. European Journal of Cancer 37(Suppl 6): S385
Meijnen, P.; Rutgers, E.J.T.; Van, D.V.lde, C.J.H.; Van Tienhoven, G.; Distante, V.; Duez, N. 2004: EORTC 10981-22023 trial AMAROS after mapping of the axilla radiotherapy or surgery? Trial update. EJC Suppls 2(3): 79
Leahy, M.G.; Blay, J.Y.; Verweij, J.; Le Cesne, A.; Duffaud, F.; Hogendoorn, P.C.W.; De Balincourt, C.; Evrard, V.; Judson, I. 2003: EORTC 62011 Phase II trial of brostallicin for soft tissue sarcoma. EJC Suppls 1(5): S209
De Reijke, T.M.; Collette, L. 2002: EORTC prostate cancer trials: what have we learnt?. Critical Reviews in Oncology/Hematology 43(2): 159-165
Bernier, J.; Horiot, J.C.; Van Den Bogaert, W.; Begg, A.; Van Glabbeke, M.; Collette, L.; Pierart, M. 2000: EORTC update of the head and neck cancer altered fractionation phase III trials. Radiotherapy and Oncology 56(Suppl 1): S8
Klapdor, R.; Fenner, C. 2002: EOSPC Imaging methods and/vs tumor markers in the follow-up. Anticancer Research 22(1B): 472
Barrett, J.A.; Kolodziej, A.F.; Caravan, P.D.; Nair, S.; Looby, R.; Witte, S.; Costello, C.R.; Melisi, M.A.; Drezwecki, L.; Chesna, C.; Pratt, C.; Mcmurry, T. 2002: EP-1873 a gadolinium labeled fibrin specific agent that rapidly detects arterial and venous thrombi with MRI. Circulation 106(19): II120
Lee, K.L.; Buxton, A.E.; Hafley, G.E.; Fisher, J.D.; Prystowsky, E.N.; Josephson, M.E. 1999: EP-guided therapy reduces the risk of arrhythmic events due to the use of ICDS, but not antiarrhythmic drugs Results from MUSTT. Circulation 100(18): 1; 81
Kelley Hickie, L.P.; Kinsella, B.T. 2004: EP1 -induced cross-desensitisation of the alpha and beta isoforms of the human Thromboxane A2 receptor. FASEB Journal 18(4-5): Abstract 639
Gong, G.; Cullen, D.M.; Peyton, A.C.; Akhter, M.P.; Recker, R.R. 2000: EP1 antagonist inhibition of bone formation induced by mechanical loading. Journal of Bone and Mineral Research 15(Suppl 1): S477
Kimura, M.; Ogihara, M. 2002: EP1 receptor agonist-induced DNA synthesis and proliferation in primary cultures of adult rat hepatocytes The involvement of transforming growth factor-alpha. Japanese Journal of Pharmacology 88(Suppl 1): 164P
Ikeda, M.; Kawatani, M.; Nakamura, Y.; Ishihama, H. 2004: EP1 receptor antagonist inhibits the effects of prostaglandin on the bladder afferent activity in the rats with irritative bladder symptoms. Journal of Urology 171(4 Suppl): 462
Maruyama, T.; Koketsu, M.; Yamamoto, H.; Yamamoto, K.; Yamamoto, L.T.; Hayashida, K.I.; Ohuchida, S.; Kondo, K. 1999: EP1 receptor antagonists suppress tactile allodynia in rats. Prostaglandins and Other Lipid Mediators 59(1-6): 217
Cullen, D.M.; Peyton, A.C.; Akhter, M.P.; Gong, G.; Johnson, M.L. 2000: EP1 receptor knockout mice response to mechanical loading. Journal of Bone and Mineral Research 15(Suppl 1): S476
Woodward, D.F. 2000: EP2 -receptor agonists as neuroprotective agents for the eye. Official Gazette of the United States Patent and Trademark Office Patents 1236(3)
Gu, Q.; Kwong, K.; Lin, Y.S.; Lee, L.Y. 2002: EP2 and EP4 prostanoid receptors mediate prostaglandin E2-induced hypersensitivity in rat vagal capsaicin-sensitive neurons In vivo and in vitro studies. FASEB Journal 16(4): A454
Houchen, C.W.; Sturmoski, M.A.; Stenson, W.F. 2000: EP2 and EP4 receptors are expressed throughout the adult mouse gastrointestinal tract and their expression levels are increased following radiation injury. Gastroenterology 118(4 Suppl 2 Pt 1): AGA A824
Houchen, C.W.; Dieckgraefe, B.K.; Sturmoski, M.A.; Stenson, W.F. 2001: EP2 receptor null mice have an impaired intestinal response to radiation injury. Gastroenterology 120(5 Suppl 1): A 10
Liu, X.; Insel, P.A.; Ostrom, R.S. 2003: EP2, EP4 and IP receptors are expressed in pulmonary fibroblasts and mediate inhibition of cell proliferation and collagen synthesis. FASEB Journal 17(4-5): Abstract
Kamiyama, M.; Pozzi, A.; Yang, L.; Debusk, L.; Breyer, R.; Jensen, R.; Lin, C. 2003: EP2, a prostaglandin E2 receptor, regulates tumor angiogenesis. Proceedings of the American Association for Cancer Research 44: 788-789
Mouihate, A.; Pittman, O.J. 1999: EP3 mRNA is localized in area of the rat brain responsive to PGE2-induced fever. Society for Neuroscience Abstracts 25(1-2): 1695
Pentland, A.P.; Han, R.; Shenkut, E.; Khan, N.; Konger, R. 2000: EP3-dependent signaling inhibits keratinocyte growth A putative mechanism for cancer chemoprevention by selective COX-2 inhibitors. Journal of Investigative Dermatology 114(4): 763
Taniguchi, T.; Tanaka, T.; Suzuki, F.; Muramatsu, I. 2002: EP4 agonist, AE1, abrogates indomethasin-induced Ductus Arteriosus constriction in utero. Japanese Journal of Pharmacology 88(Suppl 1): 270P
Davis, R.; Murdoch, C.; Sheldrick, R.; Clark, K.; Coleman, R. 2003: EP4 prostanoid receptors mediate PGE2-induced vasodilatation of human cerebral artery. Cephalalgia 23(7): 732
Davis, R.J.; Ali, M.; Sheldrick, R.L.G.; Clark, K.L.; Coleman, R.A. 2003: EP4 prostanoid receptors mediate relaxation of human cerebral artery. British Journal of Pharmacology 138(Proceedings Suppl): 153P
Cameron, K.O.; Ke, H.; Lefker, B.A.; Thompson, D.D. 2003: EP4 receptor selective agonists in the treatment of osteoporosis. Official Gazette of the United States Patent and Trademark Office Patents 1276(1)
Fernandez, I.; Pallaro, A.N.; Feliu, M.S.; Slobodianik, N. 2003: EPA and DHA supplementation versus a commercial milk enriched with linoleic and linolenic acids effects on lipids profile. FASEB Journal 17(4-5): Abstract 444
Matten, S.R. 2001: EPA and regulation of pesticide resistance management Protection of Bt. Phytopathology 91(6 Suppl): S169
Rice, D.C. 2002: EPA hazard assessment for methylmercury relies on recent epidemiological studies. Neurotoxicology and Teratology 24(3): 423-424
Edelman, D.L.; Anderson, J. 2001: EPA method 4425 Screening method for dioxin and dioxin-like compounds. Abstracts of Papers American Chemical Society 222(1-2): ENVR82
Loukas,V.; Dimizas,C.; Sinanoglou,V.J.; Miniadis-Meimaroglou,S. 2010: EPA, DHA, cholesterol and phospholipid content in Pagrus pagrus , Trachinus draco and Trigla lyra from Mediterranean Sea. Chemistry And Physics of Lipids 3(3): 292-299
Lasat, M. 2002: EPA-funded extramural research in hazardous waste management. Abstracts of Papers American Chemical Society 224(1-2): IEC 69
Caputa, M.D.; Lee, Y.S.; Han, T.; Wander, R.C. 2001: EPA/DHA-rich fish oil supplementation does not enhance in vivo and ex vivo LDL oxidation. Free Radical Biology and Medicine 31(10): S29
Sato, M.; Tanaka, T.; Uchiyama, T.; Sato, H.; Tamura, J.; Sakamoto, H.; Kurabayashi, M. 2002: EPAS1 activates the PAI-1 gene promoter through its high affinity binding sequence and through physical interaction with Sp1. Circulation 106(19): II80
Cooney, C.M.; Gilman, P. 2004: EPA's first science advisor focuses on the basics. Environmental Science and Technology 38(10): 181a-184a
Moss, K.T.; Boethling, R.S. 1999: EPAs new chemicals program PBT chemical category. Abstracts of Papers American Chemical Society 217(1-2): ENVR 127
Parry, R. 2001: EPAs vision The next steps. Journal of Dairy Science 84(Suppl 1): 3
Stulak, J.M.; Caccitolo, J.A.; Takayama, H.; Hisamochi, K.; Pearson, P.J.; Schaff, H.V. 1999: EPC A novel free radical scavenger which prevents hypoxia induced vascular injury. FASEB Journal 13(4 Part 1): A23
Matsuo, K.; Mori, S.; Ijichi, T.; Nakajima, K.; Kokufu, T.; Ihara, N. 2002: EPC-K1 reduces the expression of inducible nitric oxide synthase in delayed neuronal death. De La Torre, Jack C , Reprint Author, Kalaria, Raj, Nakajima, Kenji, Nagata, Ken Alzheimer's disease: Vascular etiology and pathology: 292-295
Yokoi, I.; Kabuto, H.; Yamamoto, N.; Mori, A.; Ogawa, N. 2001: EPC-K1, a free radical scavenger, prevents the occurrence of epileptic discharges in a rat model of posttraumatic epilepsy. Epilepsia 42(Suppl 6): 63-64
Zecchina, G.; Bosio, S.; Brusa, E.; Rege-Cambrin, G.; Camaschella, C. 2002: Epcr 23 bp insertion in a patient with severe progressive arterial disease: a dominant loss of function mutant in conditions of increased APC request?. British Journal of Haematology 119(3): 881-882
Hecht, G.; Koutsouris, A.; Muza, M.M. 2001: EPEC infection allows migration of beta1 integrin to apical membrane which contributes to functional perturbations. Gastroenterology 120(5 Suppl 1): A 325
Muza, M.M.; Schneeberger, E.; Koutsouris, A.; Hecht, G. 2001: EPEC infection of intestinal epithelial cells induces formation of aberrant tight junction strands in the lateral membrane. Gastroenterology 120(5 Suppl 1): A109-A110
Simonovic, I.; Arpin, M.; Koutsouris, A.; Hecht, G. 2001: EPEC-activated ezrin participates in signaling that disrupts barrier function. Gastroenterology 120(5 Suppl 1): A 109
Kostovska, S.; Dejanova, V.; Tofoski, J.; Pejcheva, J.; Gerasimova, P.; Ambarkova Vilarova, E. 2002: EPH gestosis Haemostatic disorders and treatment. Vox Sanguinis 83(Suppl 2): 59-60
Flanagan, J.G.; Cheng, H.J.ng 2001: EPH receptor ligands, and uses related thereto. Official Gazette of the United States Patent and Trademark Office Patents 1248(5)
Fox, G.M.; Welcher, A.A.; Jing, S. 1999: EPH-like receptor protein tyrosine kinases. Official Gazette of the United States Patent and Trademark Office Patents 1228(2)
Tang, X.X.; Zhao, H.; Evans, A.E.; Cohn, S.L.; London, W.; Cohen, B.; Cnaan, A.; Cheung, N.K.; Brodeur, G.M.; Ikegaki, N. 2000: EPHB6, EFNB2 and EFNB3 expressions predict outcome of neuroblastoma. Proceedings of the American Association for Cancer Research 41: 414
Amador, A.G.; Righi, P.D.; Radpour, S.; Everett, E.T.; Weisberger, E.; Langer, M.; Eckert, G.J.; Christen, A.G.; Campbell, S.Jr; Summerlin, D.J.; Hartsfield, J.K.Jr 2000: EPHX1, GSTM1, GSTT1 and GSTP1 gene polymorphisms in patients with mouth and throat neoplasias. American Journal of Human Genetics 67(4 Suppl 2): 104
Masutani, Y.; Yoshikawa, T.; Aoki, S.; Ohtomo, K.; Sherbondy, A.; Napel, S. 2003: EPI distortion correction for MR-DTI by using texture memory on graphics hardware. Lemke, Heinz U , Reprint Author, Vannier, Michael W, Inamura, Kiyonari, Farman, Allan G, Doi, Kunio, Reiber, John H C Computer assisted radiology and surgery: 1315
Conesa, G.; Pujol, J.; Deus, J.; López-Obarrio, L.; Gabarrós, A.; Marnov, A.; Rodriguez, R.; Navarro, R.; Capdevila, A.; Isamat, F. 1999: EPi functional MRI: a useful tool for preoperative rolandic fissure localization. Frontiers of Radiation Therapy and Oncology 33: 23-27
Dally, M.; Havercroft, J.; Hatherley, K.; Mather, D. 2000: EPI in assessing field placement for patients treated prone on a belly board What is an appropriate format and frequency?. Radiotherapy and Oncology 56(Suppl 1): S209
Day, N.; Oakes, S.; Luben, R.; Khaw, K.T.; Bingham, S.; Welch, A.; Wareham, N. 1999: EPIC-Norfolk Study design and characteristics of the cohort. British Journal of Cancer 80(Suppl 1): 95-103
Novotny, V.; Pecenak, J.; Heretik, A.S.; Heretik, A.J.; Ritomsky, A. 2003: EPID The first epidemiological study on depression in Slovakia pharmacotherapy in depressive patients. European Neuropsychopharmacology 13(Suppl 4): S199-S200
Plattard, D.; Champleboux, G.; Vassal, P.; Troccaz, J.; Bolla, M. 1999: EPID for patient positioning in radiotherapy Calibration and image matching in the EntroPID system. Lemke, H U , Vannier, M W , Inamura, K , Farman, A G International Congress Series; Computer assisted radiology and surgery 265-269
Hancu, N.D. 2000: EPIDIAB The Romanian diabetes epidemics program Preliminary data. Diabetes Research and Clinical Practice 50(Suppl 1): S402
Kessler, M.; Panescu, V.; Ait Chalal, F.; Frimat, L.; Andre, J.L.; Terrasse, H.; Briancon, S.; Epirel Cooperative Group 1999: EPIREL A multicenter prospective study on nephrology referral of patients with ESRD. Nephrology Dialysis Transplantation 14(9): A178
L'allier, P.L.; Cura, F.A.; Sapp, S.; Lincoff, M.A.; Topol, E.J. 1999: EPISTENT A large scale randomized trial of primary versus provisional coronary stenting with background platelet glycoprotein IIb/IIIa blockade. Journal of the American College of Cardiology 33(2 Suppl A): 32A
Weinhaeusel, A.S.; Morris, M.; Waldner, P.; Antonarakis, S.E.; Haas, O.A. 2002: EPM1 methylation-analysis improves PCR testing of myoclonus epilepsy-type Unverricht Lundborg. American Journal of Human Genetics 71(4 Suppl): 387
Ehlers, Ralf Udo 2002: EPN product development From strain discovery to commercial field application. Nematology 4(2): 135
Colombo, R.; Teatini, U.; Masi, F.; Maltagliati, L.; Scilletta, A. 2002: EPO administered once weekly can identify patients with functional iron deficiency. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 716A
Dillon, S.B.; Lord, K.A. 2001: EPO primary response gene, EPRG3Spt. Official Gazette of the United States Patent and Trademark Office Patents 1251(4)
Cigarran, S.; Barril, G.; Sanz, P.; Andrino, T.; Bardon, E.; Selgas, R. 2002: EPO resistant index An effective and optimal manner of anemia management in advanced chronic kidney disease. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 673A
David, S.; Triolo, G.; Tessitore, N. 2000: EPO response in patients treated by hemodiafiltration with infusion of regenerated ultrafiltrate A protocol for a multicenter study. Nephrology Dialysis Transplantation 15(9): A163
Karlsen, T.; Resaland, G.K.; Ri Li, G.; Sivieri, M.; Witowski, S.; Yates, R.; Levine, B.D.; Stray Gundersen, J. 2001: EPO response to 24 hrs of artificial hypobaric hypoxia predicts EPO response to natural altitude. Medicine and Science in Sports and Exercise 33(5 Suppl): S98
Giraudier, S.; Quint, L.; Nataf, J.; Mayeux, P.; Casadevall, N. 2003: EPO-antibodies induced erythroblastopenia in MDS Two cases with either alpha or beta recombinant erythropoietin. Leukemia Research 27(Suppl 1): S99
Shu, Y.; Buchse, T.; Bittorf, T.; Brock, J.; Sasse, T. 2003: EPO-dependent regulation of PIAS and SOCS mRNA levels Role of EPO receptor subdomains. Blood 102(11): 169b
Rothermel, J.; Wartmann, M.; Chen, T.; Hohneker, J. 2003: EPO906 A promising novel microtubule stabilizer. Seminars in Oncology 30(3 Suppl 6): 51-55
Lin, B.K.; Catley, L.P.; Leblanc, R.; Gupta, D.; Burger, R.; Tai, Y.T.; Podar, K.; Wartmann, M.; Griffin, J.D.; Anderson, K.C. 2002: EPO906 Inhibits Cell Growth and Survival of Multiple Myeloma Cells in the Bone Marrow Microenvironment, In Vitro and In Vivo. Blood 100(11): Abstract No. 3233
Chen, T.L.; Migoya, E.; Cohen, P.; Pfaar, J.; Rouilly, M.; Hubert, M.; Lau, H.; Rothermel, J.; Litchmann, M.; Dimitrijevic, S.; Chen, F.; Calvert, P. 2000: EPO906 The contribution of allometric interspecies scaling to the first dose selection in man. Proceedings of the American Association for Cancer Research 41: 720
Parmenter, M.A.; Manore, M.M.; Daniels, J.T. 2001: EPOC following high intensity intermittent and moderate intensity continuous exercise. Medicine and Science in Sports and Exercise 33(5 Suppl): S73
Sletten, A. 2001: EPPO Panel on Bacterial Diseases. Bulletin OEPP 31(3): 387-389
Anonymous 2004: EPPO Standards - Efficacy evaluation of plant protection products. Bulletin OEPP 34(1): 1-3
Anonymous 2004: EPPO Standards - Good plant protection practice. Bulletin OEPP 34(1): 41-42
Anonymous 2002: EPPO Standards Safe use of biological control. Bulletin Oepp 32(3): 443-445
Roy,A.S.; Petter,F.; Griessinger,D. 2010: EPPO database on diagnostic expertise http//dceppoorg. Bulletin Oepp Eppo Bulletin: 1, 127-130
Petzold, R. 2001: EPPO is well prepared for the future. Bulletin OEPP 31(3): 339-340
Grinband, J.; Lidke, D.S.; Anderson, D.L.; Thomas, D.D.; Jardine, P.J.mes 2002: EPR analysis of a viral DNA packaging motor. Biophysical Journal 82(1 Part 2): 460a-461a
Baveye, P. 2001: EPR analysis of the distribution of a hydrophobic spin probe in suspensions of humic acids, hectorite, and aloh-humate-hectorite complexes. Abstracts of Papers American Chemical Society 222(1-2): ENVR186
Davydov, R.; Kofman, V.; Nocek, J.; Hoffman, B.M. 2003: EPR and ENDOR probing of oxyheme centers in human hemoglobin reduced at 77K Conformational substates of the oxyheme sites in the alpha and beta subunits. Journal of Inorganic Biochemistry 96(1): 123, 15 July
Lubitz, W. 2002: EPR and ENDOR studies of hydrogenase Contributions to understanding the mechanism of biological hydrogen conversion. Abstracts of Papers American Chemical Society 223(1-2): INOR 172
Davydov, R.; Hoffman, B.M.; Valentine, A.M.; Lippard, S.J.; Sligar, S.G.; Ikeda Saito, M. 1999: EPR and ENDOR studies on cryoreduced metalloproteins. Journal of Inorganic Biochemistry 74(1-4): 110
Wang, W.; Mitic, N.; Caradonna, J.; Peisach, J. 1999: EPR and ESEEM studies of phenylalanine hydroxylase. FASEB Journal 13(7): A1499
Jin, W.; Yang, L.; Crans, D.C. 2002: EPR and NMR spectroscopy studies on the solution chemistry of vanadium dipicolinate and chelidamate complexes. Abstracts of Papers American Chemical Society 224(1-2): INOR 170
Schmidt, P.P.; Martinez, A.; Barra, A.L.; Flatmark, T.; Andersson, K.K. 1999: EPR characterisations of mononuclear iron in recombinant human phenylalanine hydroxylase, chelated models, and transferrin at various frequencies. Journal of Inorganic Biochemistry 74(1-4): 289
Britt, R.D.; Peloquin, J.M.; Campbell, K.A.; Clemens, K.; Evanchik, M. 1999: EPR characterization of the Photosystem II Oxygen Evolving Complex. Journal of Inorganic Biochemistry 74(1-4): 13
Khaled, M.M. 1999: EPR detection and properties of naturally occurring free radicals in mediterranean tobacco blends. Abstracts of Papers American Chemical Society 218(1-2): ENVR 114
Velayutham, M.; Villamena, F.; Fishbein, J.; Zweier, J. 2003: EPR detection of glutathione dependent production of oxygen free radicals by the major metabolite of the cancer chemo-preventive oltipraz using alternative precursor. Free Radical Biology and Medicine 35(Suppl 1): S172
Qian, S.Y.; Wang, H.; Schafer, F.; Buettner, G.R. 1999: EPR detection of lipid-derived radicals from peroxidations of PUFA, LDL, and cells. Free Radical Biology and Medicine 27(Suppl 1): S133
Sigurdsson, S.T.; Edwards, T.E. 2003: EPR dynamic signatures of TAR RNA bound to peptides and small molecules provide insight into RNA structure and recognition. Biophysical Journal 84(2 Part 2): 183a-184a
Mccormick, M.L.; Reszka, K.J.; Hazen, S.L.; Buettner, G.R.; Britigan, B.E. 1999: EPR evidence for peroxidase-dependent formation of a nitrite-derived oxidant. Free Radical Biology and Medicine 27(Suppl 1): S81
Hayashi, Y.; Ueda, Y.; Nakajima, A.; Yokoyama, H.; Ohya, H.; Kamada, H.; Mitsuyama, Y. 2000: EPR evidence of ROS, free radicals and lipid peroxidation produced in NMDA-stimulated PC-12 cells. Neuroscience Research Suppl (24): S83
Schaich, K.M. 2000: EPR methods for detecting and identifying free radicals in foods. Abstracts of Papers American Chemical Society 219(1-2): AGFD 110
Raczek, J.; Robert, A.; Janusz, A.; Pajak, S.; Elas, M.; Lukiewicz, S. 1999: EPR monitoring of nitric oxide in murine lymphoma upon X-irradiation combined with non-specific immunostimulation. Acta Physiologica Scandinavica 167(Suppl 645): 96
Antholine, W.E.; Kelly, B.S.; Bennett, B.; Griffith, O.W. 2003: EPR of monoMn-, MnMn-, ZnMn-, and FeFe-sites in gamma-GCS plus substrates or inhibitors. Journal of Inorganic Biochemistry 96(1): 92, 15 July
Beinert, H. 2003: EPR on the P450(cam) system in the late 1960s with Gunny and his gang: insights concerning the structure of Fe-S proteins and the spin states of P450. Biochemical and Biophysical Research Communications 312(1): 45-47
Velan, S.S.; Kuppusamy, P.; Petersen, E.; Zweier, J.L.; Fishbein, K.W.; Spencer, R.G.S. 1999: EPR oximetry mapping of cartilage formed in a hollow fiber bioreactor. Biophysical Journal 76(1 Part 2): A357
Sorlie, M.; Christansen, J.; Dean, D.; Hales, B. 1999: EPR signals observed with the alpha-H195Q mutant MoFe protein of nitrogenase during enzymatic turnover in the presence of acetylene. Journal of Inorganic Biochemistry 74(1-4): 301
Roopnarine, O.; Timm, R.; Meland, W. 2000: EPR spectroscopic and structural dynamics of FHC-mutant myosin regulatory light chains in muscle fibers. Biophysical Journal 78(1 Part 2): 115A
Bailey, D.M.; Davies, B.; Young, I.S.; Jackson, M.J.; Davison, G.W.; Isaacson, R.; Richardson, R.S. 2002: EPR spectroscopic evidence for free radical outflow by contracting human skeletal muscle Significance of intracellular oxygenation. Journal of Physiology (Cambridge) 543P: 91P-92P
Bailey, D.M.; Davies, B.; Young, L.S.; Jackson, M.J.; Davison, G.W.; Isaacson, R.; Richardson, R.S. 2002: EPR spectroscopic evidence for free radical outflow from exercising human skeletal muscle. Medicine and Science in Sports and Exercise 34(5 Suppl): S241
Pieper, G.M.; Roza, A.M.; Felix, C.C.; Adams, M.B.; Lai, C.S.n 1999: EPR spectroscopic evidence of altered myoglobin states in cardiac allograft rejection. Free Radical Biology and Medicine 27(Suppl 1): S84
Lorigan, G.A.; Cardon, T.B. 2001: EPR spectroscopic studies of magnetically oriented phospholipid bilayers. Biophysical Journal 80(1 Part 2): 518a-519a
Prisner, T. 2003: EPR spectroscopical characterization of the first electron ecceptor in cytochrome c oxidase and ubiquinol oxidase complexes. European Biophysics Journal 32(3): 169
Jaszewski, A.R.; Fann, Y.; Chen, Y.R.; Sato, K.; Corbett, J.; Mason, R. 2002: EPR spectroscopy studies on the structural transition of nitrosyl hemoglobin in the arterial-venous cycle of deano-treated rats. Free Radical Biology and Medicine 33(Suppl 2): S377
Sigurdsson, S.T.; Edwards, T.E. 2004: EPR spectroscopy used to identify amino acids in a Tat-derived peptide that play a major role in formation of a specific Tat-TAR complex. Biophysical Journal 86(1): 190a-191a
Cardounel, A.J.; Xia, Y.; Vanin, A.; Biondi, R.; Paolocci, N.; Zweier, J.L. 2000: EPR spectroscopy with Fe-MGD complexes distinguishes nitric oxide and nitroxyl anion in a redox dependent manner. Free Radical Biology and Medicine 29(Suppl 1): S67
Naber, N.; Endres, N.; Vale, R.; Cooke, R. 2003: EPR spin probes on ncd. Biophysical Journal 84(2 Part 2): 443a-444a
Hurum, D.; Agrios, A.G.; Gray, K.A.; Rajh, T.; Thurnauer, M.C. 2001: EPR studies of Degussa P25 photochemistry Insight into mixed phase titanium dioxide catalytic activity. Abstracts of Papers American Chemical Society 222(1-2): ENVR55
Maskos, Z.; Sorlie, M.; Fisher, K.; Newton, W.E.; Hales, B.J. 1999: EPR studies of the MoFe proteins of nitrogenase during enzymatic turnover in the presence of carbon monoxide. Journal of Inorganic Biochemistry 74(1-4): 224
Peterson, S.; Ahrling, K.A.; Hogblom, J.; Styring, S. 2001: EPR studies of the oxygen-evolving complex reveal a light-adaptation process in photosystem II. Photosynthesis Research 69(1-3): 96-97
Fu, Z.; Backer, J.; Gerfen, G. 2002: EPR studies on the p85 regulatory subunit of PI3-kinase. FASEB Journal 16(4): A539-A540
Yamada, S.; Matsuda, Y.; Kawamori, A. 2001: EPR study of light induced activity of spin labeled Chlorella cells. Plant and Cell Physiology 42(Suppl): s164
Nascimento, O.R.; Zucchi, M.R.; Nantes, I.L.; Faljoni Alario, A. 2000: EPR study of lipid spin label interaction with cytochrome C to understand cytochrome C/membranes association. European Biophysics Journal 29(4-5): 305
Millemon, L.F.; Hicks, B.W.; Gardner, K.A. 2003: EPR study of the DNA binding of a cisplatin analogue. Abstracts of Papers American Chemical Society 225(1-2): CHED 890
Lakshmi, K.V.; Johnson, W.T.; Golbeck, J.H.; Brudvig, G.W. 2004: EPR study on the arrangement of the terminal clusters in the reaction center of green sulfur bacteria. Biophysical Journal 86(1): 147a-148a
Yamada, S.; Matsuda, Y.; Kawamori, A. 2001: EPR study on the photo-reduction of spin probe in the green alga Chlorella ellipsoidea. Photosynthesis Research 69(1-3): 162
Chandra, S.; Gupta, L.K.mar 2004: EPR, IR and electronic spectral studies on Mn , Co , Ni and Cu complexes with a new 22-membered azamacrocyclic ligand. Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy 60(8-9): 1751-1761
Troup, G.J.; Hunter, C.R. 2002: EPR, free radicals, wine, and the industry: some achievements. Annals of the new York Academy of Sciences 957: 345-347
Chandra, S.; Sangeetika, X. 2004: EPR, magnetic and spectral studies of copper and nickel complexes of Schiff base macrocyclic ligand derived from thiosemicarbazide and glyoxal. Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy 60A(1-2): 147-153
Tao, F. 2003: EPR1 anti-epithelial surface protein. Hybridoma and Hybridomics 22(2): 133
Zisu, B.; Harvey, G.; Shah, N.P. 2003: EPS and lactic acid production by S thermophilus 1275 Influence of pH, temperature, nutrients and co-culturing with non-EPS starter. Journal of Dairy Science 86(Suppl 1): 360
Sowinski, K.; Henderson, J.; Woleck, H. 2004: EPTFE graft with axial elongation properties. Official Gazette of the United States Patent and Trademark Office Patents 1281(1)
Lentz, D.J.; Dormier, E. 1999: EPTFE graft-stent composite device. Official Gazette of the United States Patent and Trademark Office Patents 1227(1)
Patnaik, B.K.; Lin, H.B.; Lentz, D.J.; Zdrahala, R.J. 2001: EPTFE small caliber vascular grafts with significant patency enhancement via a surface coating which contains covalently bonded heparin. Official Gazette of the United States Patent and Trademark Office Patents 1251(4)
Townsend, L.E.; Park, D.; Markham, K.; Callahan, R.E.; Bendick, P.J.; Glover, J.L. 2000: EPTFE vascular grafts seeded with endothelial cells derived from stem cells in peripheral blood remain patent for six months in the canine carotid interposition model. Journal of Submicroscopic Cytology and Pathology 32(3): 409
Mazziotta, D. 1999: EQA A tool for education. Clinical Chemistry and Laboratory Medicine 37(SPEC Suppl ): S53
Secchiero, S.; Sciacovelli, L.; Siviero, A.; Bonvicini, P.; Plebani, M. 1999: EQA Programs for Biomedical Research Centers trial on the post-analytical phase. Clinical Chemistry and Laboratory Medicine 37(SPEC Suppl ): S282
Bartos, V.; Zavada, M.; Safarcik, K. 1999: EQA for tumour markers in the Czech Republic. Clinical Chemistry and Laboratory Medicine 37(SPEC Suppl ): S280
Taruscio, D.; Floridia, G.; Marongiu, S.; Salvatore, M. 2003: EQA in classical cytogenetics The Italian experience. Annales de Genetique 46(2-3): 294-296
Simola, K.O.J. 2003: EQA in classical cytogenetics The Labquality experience. Annales de Genetique 46(2-3): 82
Zucchelli, G.; Pilo, A.; Chiesa, M.; Conte, R.; Mercuri, A.; Cohen, R. 2003: EQA scheme for hormone immunoassay Evaluation of laboratory performance through a scoring system. Clinical Chemistry 49(S6): A49
Girdler, F.; Clayton, S.J.; Walker, J.; Browell, D.A.; Fox, J.C.; Brotherick, I.; Cunliffe, W.J.; Higgs, M.J.; Hemming, D.; Lennard, T.W.J.; Young, J.R.; Shenton, B.K. 2002: ER alpha and ER alpha exon5 expression in tamoxifen treated tumours. Cytometry Suppl (11): 117
Suger, F.; Gillberg, P.; Brandstrom, H.; Melhus, H.; Michaelsson, K.; Kindmarl, A. 2001: ER alpha, AR and VDR polymorphisms in a longitudinal study of healthy males Association to BMD and hormone levels. Journal of Bone and Mineral Research 16(Suppl 1): S352
Mohsin, S.K.; Hilsenbeck, S.G.; Osborne, C.K.; Allred, D.C. 1999: ER and PGR in premalignant breast lesions and normal breast epithelium. Breast Cancer Research and Treatment 57(1): 117
Allred, D.C.; Hilsenbeck, S.G.; Mohsin, S.K.; Clark, G.M.; Osborne, C.K. 1999: ER and PGR status of normal epithelium and premalignant lesions are not prognostic for breast cancer. Breast Cancer Research and Treatment 57(1): 118
Dookeran, K.A.; Gao, X.; Yang, J.; Ferrer, K.; Sekosan, M.; Sciupokiene, E.; Mackeviciute, A.; Zaren, H.A. 2003: ER beta expression parallels ER alpha/PR expression and is inversely related to EGFR expression in African American women with breast cancer. Breast Cancer Research and Treatment 82(Suppl 1): S63
Ashby, M.C.; Tepikin, A.V. 2001: ER calcium and the functions of intracellular organelles. Seminars in Cell and Developmental Biology 12(1): 11-17
Pozzan, T. 2002: ER calcium movements. Journal of Physiology (Cambridge) 543P: 11S
Antonny, B.; Schekman, R. 2001: ER export: public transportation by the COPII coach. Current Opinion in Cell Biology 13(4): 438-443
Maccioni, H.J.F.; Giraudo, C. 2003: ER export of glycosyltransferases depends on interaction of a cytoplasmic di-basic motif with SAR-1. Journal of Neurochemistry 87(Suppl 1): 119
Heiland, I.; Erdmann, R. 2001: ER involvement in peroxisome biogenesis?. Biology of the Cell 93(3-4): 247
Hampton, R.; Bays, N.; Cronin, S.; Defries, J.; Gardner, R.; Kaiser, M.; Shearer, A.; Travato, M. 2001: ER protein degradation and cholesterol regulation. FASEB Journal 15(4): A13
Brodsky, J.L.; McCracken, A.A. 1999: ER protein quality control and proteasome-mediated protein degradation. Seminars in Cell and Developmental Biology 10(5): 507-513
Ellgaard, L.; Helenius, A. 2001: ER quality control: towards an understanding at the molecular level. Current Opinion in Cell Biology 13(4): 431-437
Kohno, K. 2002: ER quality control and its stress response. Cell Structure and Function 27(4): 228
Spiliotis, E.T.; Edidin, M. 2000: ER retention and degradation of unassembled MHC class I molecules. Molecular Biology of the Cell 11(Suppl): 493a-494a
Gass, J.N.; Brewer, J.W. 2003: ER signaling in plasma cells PERK kinase and translational regulation. FASEB Journal 17(7): C209
Bown, C.; Wang, J.F.; Macqueen, G.; Young, L.T. 1999: ER stress proteins in mood disorders. Society for Neuroscience Abstracts 25(1-2): 1321
Iwawaki, T.; Hosoda, A.; Kohno, K. 2001: ER stress response in mammalian cells. Cell Structure and Function 26(5): 501
Nozaki, J.I.; Hiroshi, K.; Yoshida, H.; Naitoh, M.; Yoshinaga, T.; Mori, K.; Koizumi, A.; Nagata, K. 2002: ER stress response in pancreatic beta-cell line established from Insulin-Akita mouse. Cell Structure and Function 27(4): 316
Shang, J.; Shen, J.; Lehrman, M.A. 2003: ER stress-dependent transcription of human genes represented on the Consortium For Functional Glycomics Glyco-gene chip. Glycobiology 13(11): 859
Gotoh, T.; Oyadomari, S.; Terada, K.; Mori, M. 2003: ER stress-mediated apoptosis and disease Regulation by hsp70/DnaJ chaperone pairs. Cell Structure and Function 28(4): 292
Tessitore, A.; Del Pilar Martin, M.; D'azzo, A. 2002: ER stress-mediated apoptosis in the CNS of the GM1 gangliosidosis murine model. American Journal of Human Genetics 71(4 Suppl): 422
Muniz, M.; Morsomme, P.; Watanabe, R.; Massner, J.; Riezman, H. 2001: ER to Golgi transport of GPI-anchored proteins. FASEB Journal 15(4): A12
Ma, D.; Jan, L.Yeh. 2002: ER transport signals and trafficking of potassium channels and receptors. Current Opinion in Neurobiology 12(3): 287-292
Gupta, A.; Deshpande, C.G.; Kidwai, N.A.; Badve, S.S. 2001: ER+ high-grade breast carcinomas do not show myoepithelial differentiation. Breast Cancer Research and Treatment 69(3): 295
Dowsett, M.; Houghton, J.; Baum, M.; Salter, J.; A'hern, R.; Iden, C.; Farndon, J. 1999: ER, PgR, c-ERBB2 and EGFR in patients randomised to adjuvant tamoxifen Cimbinations of biomarkers as discriminants of treatment benefit. Breast Cancer Research and Treatment 57(1): 61
Soper, B.W.; Lessard, M.D.; Jude, C.D.; Schuldt, A.J.; Duffy, T.M.; Vogler, C.A.; Barker, J.E. 2001: ER-MP12+ ER-MP20- ER-MP58+ macrophage precursors rapidly expand, home to multiple tissues, and clear GAG storage in a model of lysosomal storage disease. Blood 98(11 Part 1): 14a-15a
Rehman, M.I.; Bermes, A.; Lee, K.; Skaar, T.; Arefayene, M.; Li, L.; Stearns, V.; Flockhart, D.A.; Hayes, D.F. 2004: ER-alpha and ER-beta genotypes predict tamoxifen effects on serum lipids in breast cancer patients. Clinical Pharmacology and Therapeutics 75(2): P2
Couse, J.F.; Korach, K.S. 2000: ER-alpha and ER-beta knock out mouse models Relevance to human physiology and pathology. Hormone Research 53(Suppl 2): 1
Nagata, K. 2004: ER-associate degradation as a quality control mechanism of terminally misfolded proteins. Journal of Pharmacological Sciences 94(Suppl 1): 69P
Hampton, R.Y. 2002: ER-associated degradation in protein quality control and cellular regulation. Current Opinion in Cell Biology 14(4): 476-482
Christian, R.C.; Harrington, S.; Shogren, K.; Edwards, W.D.; Fitzpatrick, L.A. 2001: ER-beta expression correlates with coronary calcification and atherosclerotic plaque in postmenopausal women. Journal of the American College of Cardiology 37(2 Suppl A): 288A
Hooshdaran, M.Z.; Raghow, S.; Steiner, M.S. 2002: ER-beta expression during mouse prostate carcinogenesis. Journal of Urology 167(4 Suppl): 53
Chen, J.; Yager, J.D. 2002: ER-beta-mediated estrogen induction of mitochondrial DNA -encoded transcript levels in human breast cancer MCF-7 cells. Proceedings of the American Association for Cancer Research 43: 229
Houde, M.; Bertholet, S.; Gagnon, E.; Brunet, S.; Goyette, G.; Laplante, A.; Princiotta, M.; Thibault, P.; Sacks, D.; Desjardins, M. 2003: ER-mediated phagocytosis Phagosomes are competent organelles for antigen cross presentation. Molecular and Cellular Proteomics 2(9): 804
Jensen, E.V.; Thulin Andersson, C.; Witte, A.; Warner, M.; Gustafsson, J.A.; Skoog, L. 2000: ER-positive breast cancers resistant to antiestrogen therapy. Molecular and Cellular Endocrinology 164(1-2): 259
Adebamowo, C.A.; Ogundiran, T.O.; Akang, E.E.; Adams Campbell, L.L. 2003: ER/PR status of Nigerian breast cancer patients. Proceedings of the American Association for Cancer Research 44: 306
Colegrove, S.L.; Pivovarova, N.B.; Hongpaisan, J.; Andrews, S.B.; Friel, D.D. 1999: ER/mitochondrial interactions in Ca2+ signaling in sympathetic neurons. Physiological Research 48(Suppl 1): S17
Dhulipala, P.D.K.; Reddy, S.P.; Rao, V.N. 2001: ER81 and EWS-ER81 show target specific differential transcription activation properties. FASEB Journal 15(4): A205
Kabir, Z. 2003: ERA in International Health: an experiment worthwhile?. Lancet 361(9356): 534
Sharma, M.R.; Barat, C.; Wilson, D.N.; Takemoto, C.; Booth, T.; Yokoyama, S.; Paola, F.; Agrawal, R.K. 2004: ERA protein binds in a functionally important region of the 30S ribosomal subunit. Biophysical Journal 86(1): 316a-317a
Sewell, J.M.; Gilmour, L.M.R.; Smyth, J.F.; Langdon, S.P. 2001: ERBB receptor activation is associated with growth, migration and morphogenesis in ovarian cancer. British Journal of Cancer 85(Suppl 1): 56
Schmidt Ullrich, R.K.; Bowers, G.; Dent, P.; Reardon, D.; Contessa, J.; Valerie, K. 1999: ERBB receptor tyrosine kinases as determinants of cytoprotective and cytotoxic radiation responses of carcinoma cells. International Journal of Radiation Oncology Biology Physics 45(3 Suppl): 161-162
Piechocki, M.P.; Pilon, S.A.; Wei, W.Z. 2000: ERBB-2 DNA vaccines containing EBV Gly-Ala or Pro-Ala repeat sequence. Proceedings of the American Association for Cancer Research 41: 796
Piechocki, M.P.; Pilon, S.; Wei, W.Z. 2000: ERBB-2 with glycine-alanine repeat insertion was processed by proteosome and induced tumor rejection. FASEB Journal 14(6): A1003
Lerebours, F.; Onody, P.; Tozlu, S.; Hacene, K.; Andrieu, C.; Vidaud, M.; Tubiana Hulin, M.; Spyratos, F.; Rouesse, J.; Lidereau, R.; Bieche, I. 2001: ERBB2 as a predictor of the response to endocrine therapy in postmenopausal breast carcinoma. Proceedings of the American Association for Cancer Research 42: 856
Tammela, T.L.; Savinainen, K.J.; Saramaki, O.R.; Linja, M.J.; Bratt, O.; Isola, J.J.; Visakorpi, T. 2002: ERBB2 oncogene is not amplified or overexpressed in prostate cancer. Journal of Urology 167(4 Suppl): 137-138
Frank, A.J.; Hernan, R.; Calabrese, C.R.; Gilbertson, R.J. 2002: ERBB2 overexpression alters the cell cycle, apoptosis and gene transcription profiles of medulloblastoma cells in vitro. Proceedings of the American Association for Cancer Research 43: 721
Ko, J.; Na, M.; Kim, S.; Lee, J.R.; Kim, E. 2004: ERC family of rim-binding proteins associates with the liprin-alpha family of multidomain proteins. Journal of Neurochemistry 88(Suppl 1): 29
Park, D.J.; Stoehlmacher, J.; Zhang, W.; Tsao Wei, D.; Groshen, S.; Zahedy, S.; Gil, J.; Mallik, N.; Lenz, H.J.sef 2002: ERCC1 polymorphism is associated with differential ERCC1 mRNA levels. Proceedings of the American Association for Cancer Research 43: 321
Von Hoff, D.D.; Han, H.; Nagle, R.B.; Bearss, D.J. 2003: ERCC3 expression-status in patients with pancreatic cancer. Proceedings of the American Association for Cancer Research 44: 1087
Swaminathan, K.; Kapur, K.; James, G. 2000: ERCP Tertiary centres only?. Gut 46(11): A16
Futuh, Ashraf Abul; Hamed, Waleed; Soliman, Abdel Ghany; El Hadad, Salwa; Omar, Mahmoud; El Hendawy, Sayed 2002: ERCP approach in juxtapapillary diverticulum. Journal of Hepatology 36(Suppl 1): 196
Eng, S.C.; Lee, S.D.; Kimmey, M.B.; Tung, B.Y.; Saunders, M.D.; Kowdley, K.V. 2001: ERCP associated complications in patients with primary sclerosing cholangitis. Hepatology 34(4 Pt 2): 524A
Reffitt, D.; Ede, R.; Meenan, J. 2000: ERCP balloon sphincteroplasty Safe for same-day discharge. Gastroenterology 118(4 Suppl 2 Pt 1): A5
Yarze, J.C.; Herlihy, K.J.; Chase, M.P.; Fritz, H.P. 2000: ERCP experience in a community-based, private-practice setting. American Journal of Gastroenterology 95(10): 3006-3007
Rocca, R.; Masoero, G.; Ayoubi, M.; Bonardi, L.; Secreto, P.; Lombardo, L.; Coppola, F.; Tabone, M.; Ferraris, R.; Pera, A. 1999: ERCP findings in acute biliary pancreatitis. Gastroenterology 116(4 Part 2): A28
Piotrowicz, A.J.; Stoner, E.A.; Ainley, C.C. 1999: ERCP in miniature swine An improved model for pancreatic and biliary research. Gastroenterology 116(4 Part 2): A1156
Murray, I.A.; Pathmakanthan, S.; Heeley, R.; Donnelly, M.T. 2001: ERCP training in the UK at present and the likely impact of JAG recommendations. Gut 48(Suppl 1): A95
Rosati, B.; Lecchi, M.; Curia, G.; Redaelli, E.; Cassulini, R.R.; Arcangeli, A.; Crociani, O.; Olivotto, M.; Wanke, E. 1999: ERG K+ current in hypothalamic LHRH-secreting neurons. Society for Neuroscience Abstracts 25(1-2): 2247
Samson, C.M.; Christen, W.; Foster, C.S. 1999: ERG abnormalities are sensitive indicators of subclinical disease activity in patients with Birdshot Retinochoroidopathy. IOVS Investigative Ophthalmology and Visual Science 40(4): S149
Gruenauer Kloevekorn, C.; Reichel, M.B.; Froster, U.G.; Wiedemann, P. 2001: ERG abnormalities in patients with TBX5 gene mutations. IOVS Investigative Ophthalmology and Visual Science 42(4): S649
Ong, J.M.; Zorapapel, N.C.; Rich, K.A.; Aoki, A.M.; Nesburn, A.B.; Kenney, M.C. 2001: ERG amplitude loss in high cholesterol-fed apoE-deficient mice. IOVS Investigative Ophthalmology and Visual Science 42(4): S79
Ruether, K.; Frederick, J.; Krasnoperova, N.; Hoffmann, K.; Baehr, W.; Lem, J. 1999: ERG and fundus changes in mice with and without a mutant rhodopsin transgene on a null rhodopsin background. IOVS Investigative Ophthalmology and Visual Science 40(4): S203
Emmi, A.; Tozer, K.; Nguyen, L.B.; Newell, D.W. 2002: ERG channels and regulation of epileptic activity Glial modulation of neuronal excitability. Epilepsia 43(Suppl 7): 256
Tanimoto, N.; Usui, T.; Takagi, M.; Hasegawa, S.; Abe, H.; Sekiya, K.; Miyakawa, Y.; Nakazawa, M. 2000: ERG findings in three siblings with X-linked juvenile retinoschisis associated with a XLRS1 Pro192Thr mutation. IOVS Investigative Ophthalmology and Visual Science 41(4): S891
Seeliger, M.W.; Apfelstedt Sylla, E.; Jaissle, G.B. 2000: ERG implicit time separates usher syndrome I and II. IOVS Investigative Ophthalmology and Visual Science 41(4): S890
Bin, L.Y.; Chang, Y. 2000: ERG in rats under chronic and acute hypoxia conditions. IOVS Investigative Ophthalmology and Visual Science 41(4): S17
Sakai, T.; Calderche, J.B.; Lewis, G.P.; Linberg, K.A.; Fisher, S.K.; Jacobs, G.H. 2000: ERG indices of cone loss in an animal model for retinal detachment. IOVS Investigative Ophthalmology and Visual Science 41(4): S241
Cideciyan, A.V.; Aleman, T.S.; Montemayor, R.; Laties, A.M.; Lavail, M.M.; Jacobson, S.G. 2001: ERG model of distal rod bipolar cell pathway signaling suggests compensatory changes caused by partial photoreceptor loss. IOVS Investigative Ophthalmology and Visual Science 42(4): S70
Lei, B.; Jamison, J.A.; Bush, R.A.; Sieving, P.A. 2000: ERG phototransduction analysis in tunicamycin retinal damage in monkey and rabbit. IOVS Investigative Ophthalmology and Visual Science 41(4): S242
Curtis, Rory, A.J. 2003: ERG potassium channel. Official Gazette of the United States Patent and Trademark Office Patents 1267(2)
Usui, T.; Hasegawa, S.; Takagi, M.; Hasebe, H.; Takada, R.; Hayakawa, Y.; Tanimoto, N.; Abe, H. 1999: ERGs in a patient with unilateral helicoid peripapillary chorioretinal degeneration. IOVS Investigative Ophthalmology and Visual Science 40(4): S19
Feldman, J.; Bass, S.J.; Axin, A.; Sherman, J. 1999: ERGs in myopia. IOVS Investigative Ophthalmology and Visual Science 40(4): S449
Yuan, W.; Chai, T.J.; Miao, Z.M. 2010: ERIC-PCR identification of the spread of airborne Escherichia coli in pig houses. Science of the Total Environment 408(6): 1446-1450
Kim, H.R.; Hoque, M.; Hai, C.M. 2004: ERK 1/2 MAPK Mediates Muscarinic Receptor-induced Cytoskeletal Remodeling in Airway Smooth Muscle. FASEB Journal 18(4-5): Abstract 699
Gallagher, P.; Jemiolo, B.; Trappe, S. 2004: ERK 1/2 and TNF-alpha Responses to 12-wks of Resistance Exercise Training in Young and Old Men. FASEB Journal 18(4-5): Abstract 227
Papakrivopoulou, J.S.; Lindahl, G.; Bishop, J.E.; Laurent, G.J. 1999: ERK 1/2 and p38 map kinases differentially influence mechanical load-induced procollagen gene expression in cardiac fibroblasts. FASEB Journal 13(5 Part 2): A857
Marano, C.W.; Zachariah, J.; Rendon Huerta, E.; Mullin, J.M. 2002: ERK 1/2 is a downstream mediator of protein kinase C-induced tight junction leakiness in IEC-18 gastrointestinal epithelia. Gastroenterology 122(4 Suppl 1): A 541
Clifton, G.L.; Godwin, M.L.; Nowak, G. 2004: ERK Activation Mediates Oxidant-Induced Decreases in Complex I-Coupled Respiration in Renal Cells. FASEB Journal 18(4-5): Abstract 832
Verin, A.D.; Borbiev, T.; Liu, F.; Birukova, A.; Garcia, J.G.N. 2001: ERK MAP kinase is involved in thrombin-mediated endothelial cell barrier dysfunction. FASEB Journal 15(4): A111
Gosmanov, A.R.; Nordtvedt, N.C.; Brown, R.; Thomason, D.B. 2002: ERK MAPK activation is involved in exercise-induced regulation of skeletal muscle Na+-K+-2Cl- cotransporter -mediated potassium uptake. FASEB Journal 16(4): A448
Leung, V.W.; Johnston, L.D.; Anderson, A.E. 2003: ERK activation and Kv42 downregulation in experimental epilepsy. Epilepsia 44(Suppl 9): 196
Anderson, A.E.; Adams, J.P.; Varga, A.W.; Selcher, J.C.; Feng, J.; Trzaskos, J.M.; Sweatt, J.D. 2000: ERK activation and phosphorylation of KV42 play an essential role in the kainate model of temporal lobe epilepsy. Epilepsia 41(Suppl 7): 9
Landesberg, R.; Burke, A.B.; Thomas, S.; Katz, R.W. 2002: ERK activation in wounded osteoblasts is mediated by basic fibroblast growth factor. Journal of Bone and Mineral Research 17(Suppl 1): S426
Kim, Y.; Kim, S.; Kim, G.; Baek, J. 2002: ERK activation is necessary for RANKL expression induced by high extracellular calcium. Journal of Bone and Mineral Research 17(Suppl 1): S341
Wang, X.; Holbrook, N.J. 2000: ERK activation mediates cisplatin-induced apoptosis in HeLa cells. Proceedings of the American Association for Cancer Research 41: 401
Miyazaki, T.; Takayanagi, H.; Oda, H.; Nakamura, K.; Tanaka, S. 1999: ERK activation prevents apoptotic cell death in osteoclasts. Journal of Bone and Mineral Research 14(Suppl 1): S149
Persons, D.L.; Yazlovitskaya, E.M.; Pelling, J.C. 2000: ERK activity and regulation of p53 protein accumulation in ovarian carcinoma cell line A2780 during exposure to cisplatin. Proceedings of the American Association for Cancer Research 41: 651
Kokot, N.; Ohlen, C.; Greenberg, P.D. 2000: ERK and JNK activation are deficient in tolerant murine CD8+ T lymphocytes. Journal of Investigative Medicine 48(1): 41A
Bridle, K.R.; Li, L.; O'neill, R.; Britton, R.S.; Bacon, B.R. 1999: ERK and PI3-kinase mediate the mitogenic effect of insulin-like growth factor on hepatic stellate cells. Hepatology 30(4 Part 2): 490A
Nowak, G. 2002: ERK and PKC-alpha mediate cisplatin-induced mitochondrial dysfunction and alterations in transport functions in renal proximal tubules. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 139A
Savkovic, S.D.; Kapadia, Z.; Koutsouris, A.; Hecht, G. 2001: ERK and PKCzeta independently contribute to the EPEC-induced inflammatory response. Gastroenterology 120(5 Suppl 1): A 126
Mottet, D.; Michel, G.; Renard, P.; Ninane, N.; Raes, M.; Michiels, C. 2002: ERK and calcium in activation of HIF-1. Annals of the new York Academy of Sciences 973: 448-453
Roux, P.P.; Blenis, J. 2004: ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiology and Molecular Biology Reviews: Mmbr 68(2): 320-344
Yung, H.W.; Tolkovsky, A.M. 2003: ERK and p53 mediate distinct pathways in the control of cell death in astrocytes during oxidative stress. Journal of Neurochemistry 87(Suppl 1): 159
Todd, M.K.; Turcotte, L. 2003: ERK inhibition abolishes the contraction-induced increase in muscle FA uptake. FASEB Journal 17(4-5): Abstract 317
Ally, A.; Williams, J.M.; Gerthoffer, W.; Nauli, S.M.; Pearce, W.J. 2002: ERK inhibition attenuates 5HT-induced contractions in fetal and adult ovine cerebral arteries. FASEB Journal 16(4): A104
Mukhin, Y.rii, V.; Vlasova, Tamara, M.; Grewal, Jasjit, S.; Ullian, Michael, E.; Tholanikunnel, Baby, G.; Raymond, John, R.; Garnovskaya, Maria, N. 2001: ERK is an intermediate for rapid phosphorylation of serine795 of the retinoblastoma gene product in vascular smooth muscle cells. FASEB Journal 15(4): A205
Nowak, G. 2002: ERK mediates hyperpolarization of the mitochondrial membrane during caspase-independent apoptosis induced by cisplatin in renal cells. FASEB Journal 16(5): A957
Bost, Frederic; Caron, Leslie; Marchetti, Irene; Dani, Christian; Le Marchand Brustel, Yannick; Binetruy, Bernard 2001: ERK pathway activation by retinoic acid is required for embryonic stem cells commitment into the adipocyte lineage. Biology of the Cell 93(1-2): 111
Kar, S.; Wang, M.; Carr, B.I. 2002: ERK phosphorylation by Cpd 5, a vitamin K analog, leads to inhibition of rat liver regeneration after partial hepatectomy. FASEB Journal 16(4): A366
Xiao, D.; Pearce, W.J.; Zhang, L. 2003: ERK regulates both thick and thin filament regulatory pathways in pregnant ovine uterine artery. FASEB Journal 17(4-5): Abstract
Yu, C.F.; Roshan, B.; Cantley, L.G. 2001: ERK regulates the HGF-dependent interaction of Gab1 and the PI3-kinase. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 604A
Nakamura, H.; Tsuji, T.; Hirata, A.; Yamamoto, T. 2001: ERK regulates the formation of ruffled borders in osteoclasts. Journal of Bone and Mineral Research 16(Suppl 1): S508
Tsuchida, N.; Zhang, S.L.; Huang, L.; Arvind, R.; Ren, S.; Kaneda, Y.; Jin, F. 2002: ERK signaling in cancer cells and its new downstream targets. International Journal of Molecular Medicine 10(Suppl 1): S67
Chen, A.; Bissonnette, M.; Sitrin, M.D.; Brasitus, T.A. 2001: ERK, and its downstream target, Ets-1, are involved in the 1,25 2D3-induced inhibition of cell growth and stimulation of apoptosis in Caco-2 cells. Gastroenterology 120(5 Suppl 1): A 665
Kim, S-Ja.; Ju, J-Won.; Oh, C-Do.; Yoon, Y-Mee.; Song, W.Keun.; Kim, J-Hong.; Yoo, Y.Joon.; Bang, O-Sun.; Kang, S-Sung.; Chun, J-Soo. 2002: ERK-1/2 and p38 kinase oppositely regulate nitric oxide-induced apoptosis of chondrocytes in association with p53, caspase-3, and differentiation status. Journal of Biological Chemistry 277(2): 1332-1339
E.M.brouk, M.; Touyz, R.M.; Schiffrin, E.L. 1999: ERK-dependent signaling pathways increase c-fos expression and AP-1 binding activity Role in Ang II-stimulated vascular smooth muscle cell growth in human hypertension. Circulation 100(18): 1; 700
Sawhney, Rajinder S.; St Clair, Patricia; Le, Thy; Humphrey, Lisa; Sharma, Bhavya; Brattain, Michael G. 2002: ERK/MAPK signaling is important for cell adhesion and integrin alpha2 expression as mediated by epidermal growth factor receptor in highly malignant human colon cancer cells. Proceedings of the American Association for Cancer Research 43: 363-364
Valjent, E.; Rogard, M.; Pages, C.; Besson, M.J.; Caboche, J. 2000: ERK/MAPK signaling pathway in the striatum A possible biochemical substrate for the rewarding properties of delta9-tetrahydrocannabinol. European Journal of Neuroscience 12(Suppl 11): 204
Boulton, T.G.; Cobb, M.H.; Yancopoulos, G.D.; Nye, S.; Panayotatos, N. 2001: ERK1 MAP2 protein kinase. Official Gazette of the United States Patent and Trademark Office Patents 1251(1)
Di, Y.an, P.P.; Basbaum, Carol, B.; Wu, Reen 2001: ERK1 and ERK2 activate mucin gene transcription in response to tobacco smoke exposure in human airway epithelium. Molecular Biology of the Cell 12(Suppl): 226a-227a
Nagahara, H.; Kogiso, T.; Shiratori, K. 2003: ERK1/2 MAPK signaling promoted assembly formation of p27kip1 with CycECDK2 leading to G1 cell cycle arrest in HGF-treated HepG2 cells. Hepatology 38(4 Suppl 1): 566A
Guo, M.; Huang, Q.; Munk Martin, T.; Ustinova, E.E.; Xu, W.; Wu, M.H.; Yuan, S.Y. 2004: ERK1/2 Phosphorylation and Microvascular Hyperpermeability in Response to Advanced Glycation End Products. FASEB Journal 18(4-5): Abstract 195
Sullivan, J.A.; Di, T.; Magness, R.R.; Bird, I.M. 2000: ERK1/2 activation is necessary but not sufficient to describe bFGF and EGF induced Nitric Oxide production in an Ovine Uterine Artery Endothelial Cell Culture Model Lack of evidence for Akt mediation of Nitric Oxide production. Biology of Reproduction 62(Suppl 1): 266
Bueno, Orlando F.; De Windt, Leon J.; Tymitz, Kevin M.; Witt, Sandra A.; Kimball, Thomas R.; Klevitsky, Raisa; Hewett, Timothy E.; Peng, Chang F.; Kitsis, Richard N.; Jones, Steven P.; Lefer, David J.; Molkentin, Jeffery D. 2000: ERK1/2 activation promotes compensated cardiac hypertrophy in transgenic mice while JNK1/2 or p38 activation promotes cardiomyopathy. Circulation 102(18): 2; 288
Grenett, H.E.; Lucchesi, P.A.; Wolkowicz, P.E. 2002: ERK1/2 activity is required for downregulation of PAI-1 transcription. Alcoholism Clinical and Experimental Research 26(5 Suppl): 57A
Son, M.Y.; Park, C.; Park, J.I.; Kim, Y.S.; Paik, S.G.; Yoon, W.H.; Park, S.K.; Hwang, B.D.; Lim, K. 2003: ERK1/2 and p38 MAPK is important to TGF-B1-dependent induction of MMP-2 gene in HL-60 cells. Proceedings of the American Association for Cancer Research 44: 1010
Osawa, M.; Itoh, S.; Ohta, S.; Huang, Q.; Berk, B.C.; Marmarosh, N.L.; Che, W.; Ding, B.; Yan, C.; Abe, J.I. 2004: ERK1/2 associates with the c-met-binding domain of growth factor receptor-bound protein 2 -associated binder-1 - Role in ERK1/2 and early growth response factor-1 nuclear accumulation. Journal of Biological Chemistry 279(28): 29691-29699
Rice, P.L.; Goldberg, R.J.; Driggers, L.J.; Ahnen, D.J. 2000: ERK1/2 inactivation potentiates apoptotic induction by sulindac metabolites in human colon cancer cells. Proceedings of the American Association for Cancer Research 41: 855-856
Demeilliers, B.; Girardot, D.; Deblois, D.; Moreau, P. 2000: ERK1/2 is implicated in physiological and NOS inhibition-induced vascular protein synthesis in vivo in rats. Nitric Oxide 4(3): 248
Barrett, B.S.; Rice, P.L.; Kisley, L.R.; Dwyer Nield, L.D.; Barthel, B.; Meyer, A.M.; Thompson, D.C.; Malkinson, A.M. 2003: ERK1/2 mediates induction of pro-inflammatory enzymes by cytokines in mouse lung epithelial cells. Proceedings of the American Association for Cancer Research 44: 252
Von Harsdorf, R.; Mehrhof, F.B.; Bergmann, M.; Li, P.; Dietz, R. 1999: ERK1/2-MAP-kinase plays an important role in IGF-I mediated anti-apoptotic signaling in neonatal cardiomyocytes. Circulation 100(18): 1; 325
Jaleel, M.A.; Tsai, A.C.; Sarkar, S.; Rubin, L.P. 2004: ERK1/2-dependent regulation of human placental cell survival by SDF-1 and CXCR4. FASEB Journal 18(4-5): Abstract 451
Radomska, H.S.; Ross, S.; Zhang, P.; Wu, B.; Schaufele, F.; Macdougald, O.A.; Tenen, D.G. 2003: ERK1/2-mediated phosphorylation of serine 21 inhibits ability of C/EBPalpha to stimulate granulopoiesis. Blood 102(11): 17a
Deng, X.; Ruvolo, P.P.; Carr, B.; May, W.S. 1999: ERK2 is a physiologic staurosporine-resistant Bc12 kinase. Proceedings of the American Association for Cancer Research 40: 307
Wang, L.; Ferrari, A.C.; Liu, X.; Kreis, W.; Budman, D.R.; Adams, L.M. 2000: ERK2- dependent induction of p53 and p21WAF1/CIP1 expression by vinorelbine in prostate cancer cells. Proceedings of the American Association for Cancer Research 41: 49
Boulton, T.G.; Cobb, M.H.; Yancopoulos, G.D.; Nye, S.; Panayotatos, N. 2001: ERK3 MAP2 protein kinase. Official Gazette of the United States Patent and Trademark Office Patents 1251(3)
Jenkins, B.L.; Mehta, P.B.; Robson, C.N.; Neal, D.E.; Leung, H.Y. 2002: ERK5 expression in human prostate cancer. British Journal of Cancer 86(Suppl 1): S75
Futter, M.; Rosenblum, K.; Allman, K.; Hulme, E.C.; Skehel, P.; Carter, T.; Bliss, T.V.P. 1999: ERKII-GFP translocation to the nucleus, a possible indicator of long-term synaptic plasticity in vivo. Society for Neuroscience Abstracts 25(1-2): 1696
Seta, K.; Sadoshima, J. 2001: ERKs activated by an AT1A receptor mutant lacking heterotrimeric G protein coupling are not translocated into the nucleus. Circulation 104(17): 2; 145
Mathov, I.; Sgarlata, C.L.; Plotkin, L.I.; Leoni, J.; Bellido, T.M. 1999: ERKs and calcium channels are involved in the proliferative effect of bisphosphonates in osteoblastic cells in vitro. Journal of Bone and Mineral Research 14(Suppl 1): S468
Kousteni, S.; Bellido, T.; Han, L.; Jilka, R.L.; Manolagas, S.C. 2001: ERKs as well as PI3K/Akt, but not p38, mediate the anti-apoptotic effect of sex steroids in osteoblasts and osteocytes, in part by phosphorylating Bad. Journal of Bone and Mineral Research 16(Suppl 1): S169
Endo, S.; Launey, T. 2003: ERKs regulate cerebellar long-term depression through declustering of glutamate receptors. Neuroscience Research Suppl (26): S20
Gautreau, A.; Louvard, D.; Arpin, M. 2002: ERM proteins and NF2 tumor suppressor: the Yin and Yang of cortical actin organization and cell growth signaling. Current Opinion in Cell Biology 14(1): 104-109
Mangeat, P.; Roy, C.; Martin, M. 1999: ERM proteins in cell adhesion and membrane dynamics. Trends in Cell Biology 9(5): 187-192
Fouassier, L.; Duan, C.; Yun, C.C.; Fitz, J.G.; Doctor, R.B. 1999: ERM-binding phosphoprotein, a cytoskeletal linking protein, is expressed in liver epithelial cells. Hepatology 30(4 Part 2): 505A
Wissler, J.H.; Logemann, E. 2001: ERNA in extracellular communication -metalloregulated binding to S100-EF-hand proteins bioactive in non-mitogenic angio-morphogenesis, hematopoiesis and transfer of delayed-type hypersensitivity. FASEB Journal 15(4): A189, Ch 7
Chahoud, I.; Kuriyama, S.; Fidalgo Neto, A.A.; Wittfoht, W. 2003: EROD, UDPGT activity and thyroid hormone level after in utero exposure to a low dose of 2,2,4,4,5 - Penta-BDE in rat offspring. Toxicology Letters (Shannon) 144(Suppl 1): s175
Tong, Y.nxia; Melara, Robert, D. 2000: ERP and behavioral effects of distractor variability on auditory selective attention. Psychophysiology 37(Suppl 1): S98
Campanella, S.; Hanoteau, C.; Bruyer, R.; Guerit, J.M.; Crommelinck, M. 1999: ERP correlates of face categorization. Society for Neuroscience Abstracts 25(1-2): 353
Duezel, E.; Vargha Khadem, F.; Heinze, H.J.; Mishkin, M. 1999: ERP evidence for recognition without episodic recollection in a patient with early hippocampal pathology. Society for Neuroscience Abstracts 25(1-2): 649
Bernat, E.; Shevrin, H. 2000: ERP evidence for unconscious aversive conditioning with unpleasant semantic stimuli. Psychophysiology 37(Suppl 1): S27
Cincotta, C.M.; Peterson, D.A.; Seger, C.A. 1999: ERP evidence of object location and identity inhibition in negative priming. Society for Neuroscience Abstracts 25(1-2): 1630
Singhal, A.; Pang, E.; Hetherington, R. 2000: ERP evidence that working memory functions as a unitary process for what-where information. Psychophysiology 37(Suppl 1): S90
Proverbio, A.M.; Esposito, P.; Zani, A. 1999: ERP indexes of early activation of left temporal cortex during visual selection of stimulus orientation. Society for Neuroscience Abstracts 25(1-2): 2059
Wright, M.J.; Hansell, N.K.; Geffen, G.M.; Geffen, L.B.; Smith, G.A.; Martin, N.G. 2000: ERP phenotypes in a genetic study of working memory. Psychophysiology 37(Suppl 1): S14
Iwaki, N.; Miyatani, M.; Toshima, T. 2000: ERP study on the effect of stimulus compatibility on error detection processing in a go/no-go task. Psychophysiology 37(Suppl 1): S50
Salisbury, D.F. 2000: ERPs during comprehension of homographs in schizophrenia. Psychophysiology 37(Suppl 1): S84
Woodward, S.A.; Mcmanis, M.H.; Kagan, J.; Deldin, P.J.; Snidman, N.; Lewis, M.; Shissler, T. 2000: ERPs from a visual oddball paradigm presented to 11-year-old children of two temperamental types. Psychophysiology 37(Suppl 1): S106
Mcneely, H.E.; Dywan, J.; Segalowitz, S.J. 2000: ERPs in the context of familiarity, stimulus categorization and emotion When familiarity meets its match. Psychophysiology 37(Suppl 1): S70
Semovski, S.V.; Mogilev, N.Y.; Schrum, C. 2000: ERS SAR and NOAA AVHRR applications to study Lake Baikal surface features. IAGLR Conference Program and Abstracts 43: A - 142
Girdler, F.; Clayton, S.J.; Walker, J.; Fox, J.C.; Brotherick, I.; Browell, D.A.; Cunliffe, W.J.; Higgs, M.J.; Hemming, D.; Lennard, T.W.J.; Young, J.R.; Shenton, B.K. 2001: ERalpha and ERalphaDELTA5 expression in tamoxifen-treated breast tumours. Breast Cancer Research and Treatment 69(3): 293
Hu, S.; Lu, S.; Kaplan, J.; Adams, M.; Nyby, J.; Simon, N. 1999: ERalpha and ERbeta receptor subtypes in mouse and monkey brain. Society for Neuroscience Abstracts 25(1-2): 614
Wade, C.B.; Shapiro, R.A.; Iverson, H.A.; Dorsa, D.M. 1999: ERalpha and ERbeta-mediated MAPK activation in transfected Rat-2 fibroblasts. Society for Neuroscience Abstracts 25(1-2): 419
Floetotto, T.; Niederacher, D.; Luke, D.; Beckmann, M.W.; Bender, H.G.; Hanstein, B. 2001: ERalpha but not ERbeta regulate the PR promoters. Journal of Cancer Research and Clinical Oncology 127(Suppl 1): S30
Tang, C.K.; Lippman, M.E. 2003: ERbB-4 targeted ribozymes. Official Gazette of the United States Patent and Trademark Office Patents 1270(3)
Gustafsson, Jan Ake 2000: ERbeta New views on estrogen action. Molecular and Cellular Endocrinology 164(1-2): 259
Waters, C.E.; Qiu, Y.; Lewis, A.E.; Langman, M.J.S.; Eggo, M.C. 2000: ERbeta expression and 17beta-oestradiol-induced apoptosis in a human colonic cancer cell line. Journal of Endocrinology 164(Suppl ): P318
Thompson, M.C.; Lynch, J.; Bhardwaj, B. 2000: ERbeta mRNA expression in human colon adenocarcinoma Caco-2 cells. Proceedings of the American Association for Cancer Research 41: 139-140
Alvey, L.C.; Suaud, L.; Kebler, C.; Rubenstein, R.C. 2003: ERp29 as a potential mediator of improved DF508-CFTR trafficking in CF epithelial cells. Pediatric Research 53(4 Part 2): 571A
Sitia, R.; Anelli, T.; Alessio, M.; Bachi, A.; Mezghrani, A.; Simmen, T.; Talamo, F. 2002: ERp44, a novel endoplasmic reticulum chaperone of the thioredoxin family. FASEB Journal 16(5): A892
Mansergh, F.C.; Wride, M.A.; Hance, J.; Bain, G.; Rancourt, D.E. 1999: ES cell neural differentiation reveals a substantial number of novel neural ESTs. American Journal of Human Genetics 65(4): A367
Gottlieb, D.; Boos, A.; O'malley, K. 1999: ES cell-derived neural cells express multiple catecholamine-related genes. Society for Neuroscience Abstracts 25(1-2): 1539
Mcdonald, J.W. 2001: ES cells and neurogenesis. Rao, Mahendra S Contemporary Neuroscience Stem cells and CNS development 207-261
Salcedo, M.; Cuevas, C.; Sanchez Puelles, J.M.; Otero, G.; Sousa, J.M. Fernandez; Avila, J.; Wandosell, F. 2003: ES-285, a novel antitumoral compound, interacts with EDG receptors. Proceedings of the American Association for Cancer Research 44: 727
Winski, S.L.; Siegel, D.; Zodrow, J.M.; Swann, E.; Moody, C.J.; Ross, D. 2000: ES936, a novel indolequinone inhibitor of NAD Hquinone oxidoreductase 1. Proceedings of the American Association for Cancer Research 41: 767
Gey van Pittius, N.C.; Warren, R.M.; van Helden, P.D. 2002: ESAT-6 and CFP-10: what is the diagnosis?. Infection and Immunity 70(11): 6509
Livermore, D.M. 1999: ESBL epidemiology and the relationships of ESBLs to other beta-lactamases. Journal of Antimicrobial ChemoTherapy 44(Suppl A): 16
Vergara, H.P.; Rappaport, Y. 1999: ESC A polygenetic seamount chain. Revista de Biologia Marina y Oceanografia 34(1): 115-118
Koertke, H.; Atmacha, N.; Vogt, P.; Krian, A.; Moosdorf, R.; Ennker, J.; Kloevekom, W.P.; Schueler, S.T.; Koerfer, R. 2001: ESCAT-II, a study on the effective control of low-dose anticoagulation following mechanical heart valve replacement. European Heart Journal 22(Abstract Suppl): 311
Stepanova, T.S.; Lebedev, K.E.; Bersnev, V.P.; Gurevich, E.Y. 1999: ESCG-tomography during stereotaxis for epilepsy. Epilepsia 40(Suppl 2): 18
Steinhoff, B. 2000: ESCOP and WHO monographs and their contribution to a harmonized assessment of efficacy and safety of herbal medicinal products. Phytomedicine 7(Suppl 2): 43-44
Miller, R.L.; Zhang, P.; Nelson, R.D. 2003: ESE-1 and ESE-2 expression in the mouse kidney. Journal of the American Society of Nephrology 14(Abstracts Issue): 545A
Gaspar, J.; Rudders, S.; Madore, R.; Grall, F.; Voland, C.; Pellacani, A.; Patel, A.; Perrella, M.A.; Libermann, T.A.; Oettgen, P. 2000: ESE-1 is a novel transcription mediator of inflammation that regulates the inducible nitric oxide synthase gene. Circulation 102(18): 2; 111
Voland, C.; Gaspar, J.; Oettgen, P. 2001: ESE-1 is a novel transcriptional mediator of vascular inflammation that interacts with HMG Y to regulate the inducible nitric oxide synthase gene. Circulation 104(17): 2; 208
Miller, R.L.; Zhang, P.; Nelson, R.D. 2004: ESE-1, 2 and 3 Transcription Factor Expression in Mouse Kidney. FASEB Journal 18(4-5): Abstract 840
Mccracken, J.L.; Singh, V.; Zhu, Z.; Davidson, V.L. 1999: ESEEM studies on substrate-generated tryptophan tryptophyl N-semiquinone in methylamine dehydrogenase. Journal of Inorganic Biochemistry 74(1-4): 298
Lepine, Jean Pierre 2004: ESEMED A pan-European study on the prevalence of affective disorders in Europe. Journal of Affective Disorders 78(Suppl 1): S40-S41
Yamashita, S.; Yamada, M.; Iwamoto, H. 2000: ESES syndrome with acquired aphasia. Epilepsia 41(Suppl 9): 71
Komaba, S.; Tashiro, H.; Noguchi, M.; Sanaka, T.; Gotoh, M.; Kawasugi, K.; Shirafuji, N. 2002: ESHAP Plus Rituximab Regimen for Relapsing or Refractory Non-Hodgkins Lymphoma Study of Four Cases. Blood 100(11): Abstract No. 4746
Venugopal, P.; Gregory, S.A.; Showel, J.L.; Enschede, S.H.; Shammo, J.M.; O'brien, T.M.; Friker, K.; Means, A.; Sokolovsky, T.B.; Nathan, S.; Robin, E.L. 2003: ESHAP combined with Rituximab and GMCSF is highly active in relapsed/refractory aggressive lymphoma. Blood 102(11): 307b
Claverol, S.; Uttenweiler, S.; Gairin, J.E.; Burlet Schiltz, O.; Monsarrat, B. 2003: ESI MSn analyses of intact proteins eluted from SDS PAGE gels to characterize protein variants and posttranslational modifications. Molecular and Cellular Proteomics 2(7 Suppl): S63
Maziarz, E.P. IIi; Liu, X.M.; Grobe, G.L.; Baker, G.A.; Bonafini, J. 2003: ESI and MALDI-TOF MS analysis of implantable device polymers and their interactions with proteins. Abstracts of Papers American Chemical Society 225(1-2): PMSE 80
Limbach, P.A.; Ragas, J.A.; Patrick, C.; Griggs, M.E.; Bailey, M. 2001: ESI- and MALDI-MS of aluminum peptides and proteins. Abstracts of Papers American Chemical Society 221(1-2): ANYL 65
Zea, C.J.; Pohl, N.L. 2003: ESI-MS assay for the rapid characterization of carbohydrate polymerizing enzymes. Abstracts of Papers American Chemical Society 226(1-2): CARB 78
Urbansky, E.T.; Magnuson, M.L. 1999: ESI-MS perchlorate analysis enhanced by organic modifiers. Abstracts of Papers American Chemical Society 218(1-2): ENVR 14
Zhou, N.; Hu, L.M.; Zhou, G.J.; Liu, Y.; Lu, K.; Zhao, Y.F. 2004: ESI-MS studies on novel liquid homo-peptide libraries and their conjugate libraries directed by phosphorus oxychloride. Letters in Peptide Science 10(1): 11-14
Dobryden, L. 2001: ESO training course Molecular Epidemiology. Eksperimental'naya Onkologiya 23(4): 299
Bodingbauer, M.; Rasoul Rockenschaub, S.; Langer, F.; Asari, R.; Sporn, H.; Pokorny, H.; Steininger, R.; Muehlbacher, F. 2001: ESP 2-Year follow-up at the Vienna transplantation center A comparative study ESP vs ETKAS. Nephrology Dialysis Transplantation 16(6): A204
Neoptolemos, J.P.; Dunn, J.A.; Moffitt, D.D.; Almond, J.; Beger, H.; Link, K.; Bassi, C.; Pederzoli, P.; Dervernis, C.; Fernandez Cruz, L.; Lacaine, F.; Spooner, D.; Kerr, D.J.; Friess, H.; Buchler, M. 2000: ESPAC-1 A European randomized study to assess the roles of adjuvant chemotherapy and adjuvant chemoradiation in resectable pancreatic cancer. Digestion 61(4): 265
Neoptolemos, J.P.; Moffitt, D.D.; Dunn, J.A.; Almond, J.; Beger, H.G.; Link, K.H.; Pederzoli, P.; Bassi, C.; Dervernis, C.; Fernandez Cruz, L.; Lacaine, F.; Spooner, D.; Kerr, D.J.; Freiss, H.; Buchler, M.W. 2001: ESPAC-1 A European, randomised study to assess the roles of adjuvant chemotherapy and chemoradiation in resectable pancreatic cancer. European Journal of Cancer 37(Suppl 6): S253
Neoptolemos, J.P.; Stocken, D.D.; Friess, H.; Bassi, C.; Dunn, J.A.; Hickey, H.; Beger, H.G.; Dervenis, C.; Olah, A.; Fernandez Cruz, L.; Lacaine, F.; Buchler, M.W. 2003: ESPAC-1 Final results of a European, randomised controlled trial to assess the roles of adjuvant chemotherapy and adjuvant chemoradiation in resectable pancreatic cancer. Pancreas 27(4): 398
Neoptolemos, J.P.; Dunn, J.A.; Moffitt, D.D.; Almond, J.; Beger, H.G.; Link, K.H.; Pederzoli, P.; Bassi, C.; Dervernis, C.; Fernandez Cruz, L.; Lacaine, F.; Spooner, D.; Kerr, D.J.; Freiss, H.; Buchler, M.W. 2000: ESPAC-1 interim results A European, randomised study to assess the roles of adjuvant chemotherapy and adjuvant chemoradiation in resectable pancreatic cancer. British Journal of Cancer 83(Suppl 1): 1
Mason, R.P.; Marchesi, E.; Rota, C.; Fann, Y.C.; Chignell, C. 1999: ESR and spin-trapping study of the free radical formation by 2,7-dichlorofluorescein and its implications for oxidative stress measurements. Free Radical Biology and Medicine 27(Suppl 1): S133
Song, Y.Z.; An, Jingyi; Jiang, Lijin 1999: ESR evidence of the photogeneration of free radicals and singlet oxygen by 15-deacetyl-13-glycine-substituted hypocrellin B. Biochimica et Biophysica Acta 1472(1-2): 307-313
Spiekermann, S.; Landmesser, U.; Dikalov, S.; Gamez, G.; Drexler, H.; Hornig, B.; Harrison, D.G. 2001: ESR measurement of vascular xanthine- and NAD H-oxidase activity in patients with coronary artery disease. Free Radical Biology and Medicine 31(10): S24
Spiekermann, S.; Landmesser, U.; Dikalov, S.; Gamez, G.; Reepschlaeger, N.; Drexler, H.; Hornig, B.; Harrison, D.G. 2002: ESR measurement of vascular xanthine-oxidase and NAD H-oxidase activity in patients with coronary artery disease. European Heart Journal 23(Abstract Suppl): 364
Chen, Y.R.; Sturgeon, B.E.; Gunther, M.R.; Mason, R.P. 1999: ESR spin trapping of the cyanyl radical in cyanide/cytochrome c oxidase and azidyl radical in azide/cytochrome c oxidase/H2O2 system. Biophysical Journal 76(1 Part 2): A257
Ge, M.; Brown, H.A.; Freed, J.H. 1999: ESR studies of ARF binding on lipid model membranes. Biophysical Journal 76(1 Part 2): A18
Smith, P.J.; Peterson, S.; Krausz, E.; Wydrzynski, T.; Pace, R.J. 2001: ESR studies on Photosystem II samples and core complexes from higher plants Implications from studies on the g41 signal. Photosynthesis Research 69(1-3): 183
Kirima, K.; Tsuchiya, K.; Hasegawa, T.; Abe, S.; Ozawa, Y.; Yoshizumi, M.; Tamaki, T. 2001: ESR study on free radical scavenging and/or generating activity of dopamine-4-O-sulfate. Japanese Journal of Pharmacology 85(Suppl 1): 259P
Silva, E.H.; Poletti, E.F.; Neves, M.A.F.S.; Schreier, S.; Coutinho, F.M.B.; Nakaie, C.R. 2003: ESR-solvation study of different amine loaded and cross-linked resins Implication for peptide synthesis and liquid chromatography. Biopolymers 71(3): 340
Ikeda, Y.; Chua, N.H.i 2002: ESR2 - a plant gene that can promote shoot regeneration. Official Gazette of the United States Patent and Trademark Office Patents 1261(4)
Agodoa, L.Y.C.; Roys, E.C.; Wolfe, R.A.; Jones, C.A.; Frankenfield, D.; Port, F.K. 1999: ESRD among Hispanics in the US. Journal of the American Society of Nephrology 10(Program and Abstr. Issue): 232A-233A
Scheinman, J.I.; Payne, R. 2002: ESRD in Sickle Cell Nephropathy, survival with and without transplantation. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 403A
Kiberd, B.A.; Clase, C.M. 2001: ESRD is a more important cause of lost life than some common malignancies in US Blacks. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 216A
Samarapungavan, D.; Gray, S.; Lester, C.; Habowski, S.; Eyzaguirre, A.; Suyo, W. 2000: ESRD patients perspective of their nephrologists role as primary care provider. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 242A
Meier Kriesche, H.U.; Schold, J.D.; Gaston, R.S.; Ettenger, R.B.; Kaplan, B. 2003: ESRD time is one of the strongest modifiable risk factors for graft loss after kidney transplantation independent of age or ethnicity. Journal of the American Society of Nephrology 14(Abstracts Issue): 665A
Avidan, A.Y.; Chervin, R.D. 2001: ESScom. Sleep 24(Abstract Suppl): A414-A415
Shimotori, T.; Takada, N.; Goto, T.; Sato, N. 2002: EST analysis of gene expression in hatchling of the arrow worm Paraspadella gotoi. Zoological Science 19(12): 1424
Kubokawa, K.; Uchida, K.; Murakami, Y.; Kuratani, S.; Mizuta, T.; Agata, K. 2003: EST analysis of gene expression in neural tube of amphioxus. Zoological Science (Tokyo) 20(12): 1598
Hasegawa, A.; Hisatomi, O.; Yamamoto, S.; Goto, T.; Sakami, S.; Tokunaga, F. 2002: EST analysis of genes expressed in regenerating newt retina. Zoological Science 19(12): 1468
Boysen, C.; Borkowski, J.A.; Candlin, J.; Herrmannsfeldt, G.; Huang, X.; Oh, K.; Paul, C.; Qian, J.; Smith, C.P.; Xu, L.; Hunkapiller, T. 2000: EST assembly using Paracels clustering package. International Genome Sequencing and Analysis Conference 12: 51-52
Stöhr, H.; Mah, N.; Schulz, H.L.; Gehrig, A.; Fröhlich, S.; Weber, B.H. 2001: EST mining of the UniGene dataset to identify retina-specific genes. Cytogenetics and Cell Genetics 91(1-4): 267-277
Kim Woonbong; Dellapenna, D. 2002: EST study of carotenoid synthesis in marigold. Plant Biology (Rockville) : 46
Anonymous 2000: ESTRO-MITRE 2000, Brussels, Belgium, December 10-11, 2000. Radiotherapy and Oncology 57(Suppl 1): S1-S53
Hoskin, P.; Chow, E.; Wu, J.; Coia, L. 2001: ESTRO/ASTRO consensus statement on the measurement of metastatic bone pain in radiotherapy trials. European Journal of Cancer 37(Suppl 6): S259
Ash, D.; Flynn, A.; Battermann, J.; de Reijke, T.; Lavagnini, P.; Blank, L. 2000: ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. RadioTherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology 57(3): 315-321
Qin, L.; Borm, T.J.A.; Bakker, J. 2002: ESTScreen Identify secretory proteins in silico. Nematology 4(2): 224
Jones, J.T.; Blok, V.C.; Prior, A.; Phillips, M.S.; Popeijus, H.; Bakker, E.; Helder, H.; Smant, G. 2000: ESTs from potato cyst nematodes From sequences to functional analysis. Nematology 2(7): 765
Xue, L.; Bingham, S.; Lippmeier, C.; Apt, K.E. 1999: ESTs from the dinoflaggellate Crypthecodinium cohnii. Plant Biology (Rockville) : 144
Jaffee, D.C.; Schulsinger, D.A. 2001: ESWL Blast from the past and the wave of the future. Journal of Urology 165(5 Suppl): 176
Kutilek, P.; Novak, I. 1999: ESWL Long-term results in treatment of urolithiasis The role of stone localization in therapy effect. Journal of Endourology 13(Suppl 1): A48
Lindqvist, K.; Holmberg, G.; Peeker, R.; Grenabo, L. 2001: ESWL as primary treatment for ureteric stone. Journal of Endourology 15(Suppl 1): A76
Demirkesen, O.; Yaycioglu, O.; Onal, B.; Kalkan, M.; Tansu, N.; Yalcin, V.; Kural, A.R.; Solok, V. 2000: ESWL for stones in abnormal urinary tracts; analysis of results and comparison with normal population. Journal of Endourology 14(Suppl 1): A82
Aboul Azm, T.; Eid, N.; Hashad, M.; Mokhless, I. 2001: ESWL in bladder stones An absolute indication. European Urology 39(Suppl 5): 60
Medin, T.; Mamatbekov, R.A. 2001: ESWL in children with nephrolithiasis. European Urology 39(Suppl 5): 59
Bergsdorf, T.; Thueroff, S.; Chaussy, C. 2004: ESWL induced ventricular arrhythmia, in fact an exogenous parasystoly. European Urology Suppls 3(2): 69
Yousuff, A.M.; Almond, D.J. 1999: ESWL monotherapy for ureteric calculi The influence of diuretic on stone clearance. Journal of Endourology 13(Suppl 1): A131
Traxer, O.; Archambaud, F.; Margaryan, M.; Mercier Pageyral, B.; Lottmann, H. 2001: ESWL monotherapy for urolithiasis in children. Journal of Endourology 15(Suppl 1): A54
Rubenstein, J.N.; Kim, S.C.; Nadler, R.B. 2001: ESWL of pancreatic duct stones The Northwestern University experience. Journal of Urology 165(5 Suppl): 375
Schumacher, M.; Unrau, J.; Gerber, R.; Schmutz, R.; Studer, U.E.; Danuser, H. 2003: ESWL of urinary stones Higher treatment efficacy with the HM3 or more patient comfort with the Modulith SLX What would the patient choose?. Journal of Urology 169(4 Suppl): 491
Jung, A.; Kaminska, A.; Zuber, J. 2001: ESWL treatment in children Results, complications and the role of endourology Own observations. Journal of Endourology 15(Suppl 1): A54
Tucak, A.; Prlic, D.; Kuvezdic, H. 2000: ESWL treatment of urinary stones in children. European Urology 37(Suppl 2): 16
Papathanasiou, A.; Salpigidis, G.; Fatles, G.; Balaxis, E.; Eleftheropoulos, O.; Vakalopoulos, K. 1999: ESWL versus URS for distal ureteral calculi. Journal of Endourology 13(Suppl 1): A72
Huang, S.H.; Chang, C.P.; Tai, H.L.; Yen, M.Y.; Wang, B.F.; Lin, J. 1999: ESWL vs URSL in the treatment of distal ureteral calculi. Journal of Endourology 13(Suppl 1): A71
Lorenzi, L.; Ceccarelli, P.; Innocenti, M.; Scala, C.; Bonicelli, P. 1999: ESWL with electroconductive lithotripter Treatment and 3 months follow-up in 288 patients. Journal of Endourology 13(Suppl 1): A73
Rompe, J.D. 2001: ESWT and calcifying tendinitis of the shoulder. Clinical Rheumatology 20(5): 417
Neururer, R.; Studen, M.; Maneschg, C.; Bartsch, G. 2002: ESWT for the treatment of induratio penis plastica Clinical outcome. Journal of Urology 167(4 Suppl): 204
Johnstrom, P.; Harris, N.G.; Fryer, T.D.; Aigbirhio, F.I.; Clark, J.C.; Pickard, J.D.; Davenport, A.P. 2001: ET-1 a PET radioligand for the endothelin receptor system Radiochemistry, position of label and in vivo biodistribution. Journal of Labelled Compounds and Radiopharmaceuticals 44(Suppl 1): S407-S409
Aharinejad, S.; Abraham, D.; Hofbauer, R.; Schaefer, R.; Kocher, A.; Blumer, R.; Nourani, F.; Laufer, G. 2000: ET-1 and VEGF mRNA expression levels correlate with mitochondrial morphology in cardiac tissues of CMP patients before and after transplantation. FASEB Journal 14(4): A464
Burgener, D.; Svenson, M.; Aneman, A.; Treggiari, M.; Strasser, S.; Hadengue, A. 2000: ET-1 antagonist restores hepatosplanchnic DO2 and corrects O2 metabolism failure in an acute hypoperfusion animal model. Gastroenterology 118(4 Suppl 2 Pt 1): AASLD A970
Goto, M.; Masuda, H.; Azuma, H. 2000: ET-1 augments the inhibition of NO generation with L-NMMA in rabbit arterial strips by increasing L-NMMA uptake. Japanese Journal of Pharmacology 82(Suppl 1): 63P
Li, L.; Xu, H.; Watts, S.W.; Galligan, J.J.; Fink, G.D.; Chen, A.F. 2002: ET-1 augments venous contractility via NADPH oxidase-induced superoxide in DOCA-salt hypertension. FASEB Journal 16(5): A1135
Thakali, K.; Watts, S.W. 2004: ET-1 contraction signaling in veins is independent of extracellular hydrogen peroxide. Hypertension 43(6): 1352, 1351
Xu, H.; Fink, G.D.; Galligan, J.J. 2001: ET-1 induced elevations in blood pressure are independent of increases in sympathetic nerve activity in normotensive rats. FASEB Journal 15(4): A230
Yu, Q.; Lal, H.; Woodward, B.; Williams, K.I. 2001: ET-1 sensitizes actions of vasoconstrictor agents in rat isolated perfused lungs. British Journal of Pharmacology 133(Proceedings Suppl): 232P
Loomis, E.D.; Pollock, D.M.; Pollock, J.S. 2003: ET-1 stimulates O2- production exerting a vasoconstrictor effect in rat aortic rings. FASEB Journal 17(4-5): Abstract 335
Rossi, G.; Andreis, P.; Neri, G.; Tortorella, C.; Pelizzo, M.; Sacchetto, A.; Nussdorfer, G. 2000: ET-1 stimulates aldosterone synthesis in Conns adenomas via ETA and ETB coupled with the PKC- and COX-dependent pathways. Journal of Hypertension 18(Suppl 4): S215
Richter, C.M.; Herzfeld, S.; Godes, M.; Schulz, N.; Slowinski, T.; Neumayer, H.H.; Bauer, C.; Hocher, B. 2003: ET-1 transgenic mice, deficient for the inducible nitric oxide synthase gene expression, develop blood pressure independent cardiac hypertrophy. Journal of the American Society of Nephrology 14(Abstracts Issue): 520A
Takanashi, M.; Miyauchi, T.; Irukayama, Y.; Sakai, S.; Kasuya, Y.; Ogata, T.; Iemitsu, M.; Sudo, T.; Goto, K.; Yamaguchi, I. 2003: ET-1-induced cardiac hypertrophy is inhibited by activation of PPAR-alpha via blockade of Jun NH2-terminal kinase pathway. Journal of Pharmacological Sciences 91(Suppl I): 104P
Beijnen, J.H.; Schellens, J.H.M. 2002: ET-743 A viewpoint. Drugs 62(8): 1193-1194
Markenson, D.; Hu, Z.; Scotto, K.W. 2001: ET-743 inhibits SP1-mediated transcriptional activation of the p21 promoter. Proceedings of the American Association for Cancer Research 42: 203
Lange, D.; Haywood, J.R.; Hinojosa Laborde, C. 1999: ET-A receptor antagonism attenuates adrenal medulluary catecholamine release in male but not female rats during hypoglycemia. FASEB Journal 13(5 Part 2): A1045
Bunker, N.; Liu, Y.; Neely, M.; Shepherd, A.M.M.; Kellogg, D.L.Jr 1999: ET-B receptor control of vascular tone in human hypertension. Journal of Investigative Medicine 47(4): 183A
Gorfajn, B.D.; Jin, S.; Hu, Z.; Scotto, K.W. 2000: ET743, a novel transcription-targeted chemotherapeutic that inhibits activation of the MDR1 promoter by multiple inducers. Proceedings of the American Association for Cancer Research 41: 804
Verma, S.; Lovren, F.; Dumont, A.; Maitland, A.; Triggle, C.R.; Anderson, T.J. 2000: ETA and ETB receptor blockade independently and maximally improve endothelial function in human internal mammary arteries. Canadian Journal of Cardiology 16(Suppl F): 214F-215F
Inscho, E.W.; Imig, J.; Pollock, D.; Cook, A. 2002: ETA and ETB receptors participate in the afferent arteriolar response to endothelin. FASEB Journal 16(4): A130
Backs, J.; Buss, S.J.; Kristen, A.; Haunstetter, A.; Haass, M. 2002: ETA antagonism enhances cardiac norepinephrine re-uptake in experimental heart failure. Circulation 106(19): II67
Francis, R.J.B.; Zhang, X.Y.; Wheatley, A.M. 1999: ETA but not ETB receptor antagonism protects the liver from hypothermic ischaemia-reperfusion injury and microhaemodynamic disturbances during liver transplantation in the rat. Hepato-Gastroenterology 46(Suppl 2): 1487
Quaschning, T.; Ruschitzka, F.T.; Lunt, C.M.B.; Niggli, B.; Shaw, S.; Luescher, T.F. 2000: ETA receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition. Kidney and Blood Pressure Research 23(3-5): 296
Quaschning, T.; Ruschitzka, F.T.; Niggli, B.; Lunt, C.C.M.; Shaw, S.; Luscher, T.F. 2000: ETA receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition Role of nitric oxide and endothelin. Circulation 102(18): 2; 169
Quaschning, T.; Ruschitzka, F.T.; Niggli, B.; Lunt, C.M.B.; Shaw, S.; Luscher, T.F. 2000: ETA receptor antagonism prevents vascular dysfunction in 11beta-hydroxysteroid dehydrogenase deficient hypertension. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 340A
Reinecke, A.; Xia, Q.; Dorenkamp, M.; Bitterling, H.; Penz, S.; Storz, C.; Simon, R.; Unger, T. 2003: ETA receptor antagonism, angiotensin type 1 receptor antagonism, angiotensin-converting enzyme inhibition and combined treatments after experimental myocardial infarction in stroke-prone spontaneously hypertensive rats. European Heart Journal 24(Abstract Suppl): 170
Park, J.B.; Schiffrin, E.L. 2000: ETA receptor antagonist prevents blood pressure elevation and vascular hypertrophy of resistance arteries in aldosterone-infused rats. Canadian Journal of Cardiology 16(Suppl F): 109F
Orth, S.R.; Karkoszka, H.; Odoni, G.; Ogata, H.; Amann, K.; Raschack, M.; Ritz, E. 2000: ETA receptor blockade and ACE inhibition inhibit chronic transplant vasculopathy in a normotensive and hypertensive aorta allotransplantation rat model. Journal of the American Society of Nephrology 11(Program and Abstract Issue): 669A
Gilbert, P.; Thorin, E. 2000: ETA receptor blockade augments endothelium-dependent and -independent NO-mediated relaxation of rabbit cerebral arteries. Circulation 102(18): 2; 171
Wedgwood, S.; Mcmullan, D.M.; Bekker, J.M.; Fineman, J.R.; Black, S.M. 2000: ETA receptor blockade preserves NOS activity during inhaled NO therapy A role for ET-1-induced superoxide production. Circulation 102(18): 2; 169
Trenkner, J.; Priem, F.; Bauer, C.; Raschak, M.; Neumayer, H.H.; Hocher, B. 2001: ETA receptor blockade reduces proteinuria and vascular hypertrophy in spontaneously hypertensive rats on high salt diet in a blood-pressure independent manner. Kidney and Blood Pressure Research 24(4-6): 335
Lavallee, M.; Thorin, E.; Parent, R. 1999: ETA receptor blockade restores flow-dependent dilation after blockade of NO formation in conscious dogs. FASEB Journal 13(5 Part 2): A783
Scherer, E.Q.; Wangemann, P. 2001: ETA receptor signaling in the spiral modiolar artery. FASEB Journal 15(4): A112
Giulumian, A.D.; Reddy, V.B.; Fuchs, L.C. 2003: ETA receptor-mediated activation of L-type and T-type calcium channels contributes to enhanced venous contraction to ET-1 in heart failure. FASEB Journal 17(4-5): Abstract 810
Rizzoni, D.; Porteri, E.; Guelfi, D.; De Ciuceis, C.; Piccoli, A.; Castellano, M.; Bettoni, G.; Sleiman, I.; Agabiti Rosei, E. 2000: ETA receptors mediate the vasoconstriction induced by endothelin-1 in subcutaneous small resistance arteries of normotensive and hypertensive subjects. European Heart Journal 21(Abstract Suppl): 487
Orth, S.R.; Adams, J.; Odoni, G.; Ogata, H.; Viedt, C.; Amann, K.; Raschack, M.; Ritz, E. 2001: ETA-receptor blockade, ACE inhibition and their combination attenuate chronic transplant nephropathy in the Fisher-to-Lewis rat model. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 863A
Nguyen, Q.T.; Cernacek, P.; Calderone, A.; Rouleau, J.L. 2000: ETA/ETB receptor blockade does not improve cardiac function and remodeling in the rat model of heart failure. Circulation 102(18): 2; 196
Pavlovska, G.; Cundeva, K.; Stafilov, T. 2002: ETAAS method for copper determination in fresh waters following flotation separation by cobalt hepthyldithiocarbamate and cobalt hexamethylenedithiocarbamate. Analytical Letters 35(14): 2347-2362
Peng, Y.; Amemiya, M.; Yang, X.; Moe, O.W.; Yin, H.; Preisig, P.A.; Yanagisawa, M.; Alpern, R.J. 1999: ETB receptor activation causes exocytic insertion of NHE3 into the apical membrane of OKP cells. Journal of the American Society of Nephrology 10(Program and Abstr. Issue): 459A
Bagnato, Anna; Rosano', Laura; Spinella, Francesca; Di Castro, Valeriana; Nicotra, Maria Rita; Natali, Pier Giorgio 2002: ETB receptor blockade inhibits melanoma cell migration, invasion, and FAK phosphorylation. Proceedings of the American Association for Cancer Research 43: 22
Vassileva, I.; Pollock, D.M. 2001: ETB receptor blockade inhibits pressure natriuresis in Sprague-Dawley rats. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 475A
Nangaku, M.; Yamada, K.; Gariepy, C.E.; Miyata, T.; Inagi, R.; Kurokawa, K.; Yanagisawa, M.; Fujita, T.; Johnson, R.J. 2002: ET(B) receptor protects the tubulointerstitium in experimental thrombotic microangiopathy. Kidney International 62(3): 922-928
Lal, H.; Williams, K.I.; Woodward, B. 1999: ETB receptor-mediated bronchoconstriction is potentiated in lungs from chronically hypoxic rats. British Journal of Pharmacology 128(Proceedings Suppl ): 70P
Reddy, V.B.; Fuchs, L.C. 2000: ETB receptor-mediated contraction to endothelin-1 is absent in mesenteric veins of cardiomyopathic hamsters. FASEB Journal 14(4): A142
Iavicoli, I.; Carelli, G. 2003: ETBE-related effects on rat fibroblasts. Toxicology Letters (Shannon) 144(Suppl 1): s42
Darsow, U.; Wollenberg, A.; Simon, D.; Taïeb, A.; Werfel, T.; Oranje, A.; Gelmetti, C.; Svensson, A.; Deleuran, M.; Calza, A-M.; Giusti, F.; Lübbe, J.; Seidenari, S.; Ring, J.; Baadsgaard, O.; Bieber, T.; Bonifazi, E.; Bruijnzeel-Koomen, C.A.F.M.; Calza, A.M.; Deleuran, M.; Darsow, U.; De la Cuadra, J.; De Raeve, L.; Diepgen, T.L.; Dupuy, P.; Fabrizi, G.; Gelmetti, C.; Giannetti, A.; Gieler, U.; Giusti, F.; Harper, J.; Holm, E.A.; Kägi, M.; Kekki, O.; Kunz, B.; Lever, R.; Lübbe, J.; Olesen, A.B.; Oranje, A.P.; de Prost, Y.; Rajka, G.; Reunala, T.; Revuz, J.; Ring, J.; Seidenari, S.; Simon, D.; Song, M.; Stalder, J.F.; Svensson, A.; Taïeb, A.; Tennstedt, D.; Turjanmaa, K.; Vestergaard, C.; Werfel, T.; Wollenberg, A. 2010: ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. Journal of the European Academy of Dermatology and Venereology: JEADV 24(3): 317-328
Petroianu, G.A.; Hein, G.; Bergler, W.F.; Hoermann, K.; Jatzko, A. 2002: ETICS-trial Results after 48 months of treatment. Clinical Pharmacology and Therapeutics 71(2): P47
Rinehart, K.L.; Morales, J.J.; Reid, J.; Reymundo, I.; Floriano, P.; Gravalos, L.G.rcia 2001: ETM-775 metabolite of ecteinascidin 743. Official Gazette of the United States Patent and Trademark Office Patents 1252(2)
Saunthararajah, Y.; Ibanez, V.; Sharma, A.; Wang, J.; Verma, A. 2002: ETO Recruitment of the Nuclear Receptor Co-Repressor and Histone Deacetylase Activity Is Required for Granulocyte but Not Monocyte Differentiation. Blood 100(11): Abstract No. 4080
Van Winkle, W.B.; Snuggs, M.B.; Jones, C.; Buja, L.M. 2001: ETOH protection against cytoskeletal damage in cardiomyocytes mediated by NFkappaB. Journal of Molecular and Cellular Cardiology 33(6): A179
Wen, C.K.; Chang, C. 1999: ETR2 may talk to CTR1 through ETR1 in ethylene signal transduction in Arabidopsis. Plant Biology (Rockville) : 50-51
Spielmann, T.; Gardiner, D.L.; Trenholme, K.R.; Beck, H.P.; Kemp, D.J. 2003: ETRAMPs are part of multiprotein complexes in the Plasmodium parasitophorous vacuole membrane. Experimental Parasitology 105(1): 66
Budhiraja, N.; Klinnert, M.D.; Anderson, L.R.; Anderson, M.; Faries, G.; Balkissoon, R.; Seelye, J.; Hovell, M. 2004: ETS as a factor in asthma morbidity in an urban pediatric population. Journal of Allergy and Clinical Immunology 113(2 Suppl): S258
Buggy, Y.; Maguire, T.M.; Mcgreal, G.; Hill, A.D.K.; Mcdermott, E.; O'higgins, N.; Duffy, M.J. 2003: ETS transcription factors in human breast cancer. British Journal of Cancer 88(Suppl 1): S48
Haremaki, T.; Tanaka, Y.; Hongo, I.; Okamoto, H. 2001: ETS- and Sox-related transcription factors are required for FGF response of Xenopus caudal gene homologue Xcad3. Development Growth and Differentiation 43(Suppl): S100
Keehn, C.A.; Smoller, B.R.; Morgan, M.B. 2003: ETS-1 oncoprotein expression and prognosis in melanocytic nevi and cutaneous melanoma. Modern Pathology 16(1): 92A-93A
Keehn, C.A.; Smoller, B.R.; Morgan, M.B. 2003: ETS-1 oncoprotein expression and prognosis in primary cutaneous carcinomas. Modern Pathology 16(1): 93A
Mavrothalassitis, G.J.; Blair, D.G.; Fisher, R.J.; Beal, G.J.; Athanasiou, M.A.; Sgouras, D.N. 2001: ETS2 repressor factor. Official Gazette of the United States Patent and Trademark Office Patents 1243(4)
Mavrothalassitis, G.J.; Blair, D.G.; Fisher, R.J.; Beal, G.J.Jr; Athanasiou, M.A.; Sgouras, D.N. 1999: ETS2 repressor factor genetic locus and its products. Official Gazette of the United States Patent and Trademark Office Patents 1218(1): 358
Fahmy, W.E.; Semenchenko, V.I.; Moussa, O.; Rashwan, H.M.; Shamaa, M.A.; Bissada, N.K.; Watson, D.K. 2003: ETS2 target genes in prostate cancer cells. Journal of Urology 169(4 Suppl): 219
Elghezal, H.; Brahim, W.; Sennana, H.; Saad, A. 2003: ETV6 gene implication in leukaemia cases with 12p13 Molecular cytogenetic Study. Annales de Genetique 46(2-3): 117
Adem, C.; Cin, P.D.; Gisselsson, D.; Nascimento, A.G. 2002: ETV6 rearrangements in infantile fibrosarcomas and congenital mesoblastic nephromas by fluorescence in situ hybridization. Laboratory Investigation 82(1): 309A
Punnett, H.H.; Tomczak, E.Z.; Pawel, B.R.; de Chadarevian, J.P.; Sorensen, P.H. 2000: ETV6-NTRK3 gene fusion in metastasizing congenital fibrosarcoma. Medical and Pediatric Oncology 35(2): 137-139
Singh, S. 2002: ETagTM reporter assay system for solution-phase multiplexing of gene expression and protein analysis. Molecular and Cellular Proteomics 1(9): 723
Ames, J.M. 2002: EU COST action 919 melanoidins in food and health. Horiuchi, Seikoh , Reprint Author, Taniguchi, Naoyuki, Hayase, Fumitaka, Kurata, Tadao, Osawa, Toshihiko The Maillard reaction in food chemistry and medical science: Update for the postgenomic era: 389-390
Mitchell, P. 1999: EU approves tighter regulations for genetically modified foods. Lancet (North American Edition) 354(917): 54
Rogiers, V. 2003: EU cosmetic directive and requirements for toxicological evaluation of cosmetic ingredients. Toxicology Letters (Shannon) 144(Suppl 1): s2-s3
Burke, M. 2004: EU funds african, Caribbean water cleanup. Environmental Science and Technology 38(11): 200A
Fletcher, A.P. 2000: EU pharmacovigilance guidelines. Review. Adverse Drug Reactions and Toxicological Reviews 19(2): 123-126
Watson, R. 1999: EU plans more antibiotic resistance surveillance. BMJ 318(7200): 1716
Petrunov, B.; Kojouharova, M.; Teoharov, P.; Haidushka, I.; Sotirova, P.; Sredkova, M.; Russev, I.; Zacharakis, G.; Tzara, F.; Vafeiadis, N.; Papathanasiou, J.; Papoutselis, K. 2002: EU project interreg II Seroepidemiology study on hepatitis C and B viral infections prevalence in Bulgaria and nothern Greece. Journal of Hepatology 36(Suppl 1): 138-139
Craven, N. 2003: EU regulation of existing authorized veterinary medicines High costs, low benefits?. Journal of Veterinary Pharmacology and Therapeutics 26(Suppl 1): 64
Munn, S.Janette.; Hansen, B.Gaarn. 2002: EU risk assessment: science and policy. Toxicology 181-182: 281-285
Kordel, W.; Terytze, K. 2004: EU soil protection - More than a memorandum of understanding?. Journal of Soils and Sediments 4(3): 143-144
Madle, S. 2000: EU technical guidance document for mutagenicity. Mutagenesis 15(5): 447
Swallow, D.M. 2003: EU-MUC5Ba and MUC5Bb against MUC5B. Hybridoma and Hybridomics 22(6): 409
Swallow, D.M. 2003: EU-MUC7a against MUC7. Hybridoma and Hybridomics 22(6): 408
Rahn, C.R.; Zhang, K.; Lillywhite, R.; Ramos, C.; Doltra, J.; Paz, J.M.; Riley, H.; Fink, M.; Nendel, C.; Thorup-Kristensen, K.; Pedersen, A.; Piro, F.; Venezia, A.; Firth, C.; Schmutz, U.; Rayns, F.; Strohmeyer, K. 2010: EU-Rotate_N - a decision support system - to predict environmental and economic consequences of the management of nitrogen fertiliser in crop rotations. European Journal Of Horticultural Science: 1, 20-32
Mounfield, H. 2004: EUCARE action pack. Epilepsia 45(Suppl 3): 3
D.Boer, H. 2004: EUCARE and the global campaign. Epilepsia 45(Suppl 3): 4
Kvale, E.O.; Patel, N.S.A.; Chatterjee, P.K.; Sharpe, M.A.; Thiemermann, C. 2002: EUK-134 reduces oxidative stress-mediated injury and death of rat proximal tubular cells. British Journal of Pharmacology 135(Proceedings Suppl): 67P
Chatterjee, P.K.; Kvale, E.O.; Patel, N.S.A.; Sharpe, M.A.; Thiemermann, C. 2001: EUK-134 reduces oxidative stress-mediated renal dysfunction and injury in the rat in vivo and in vitro. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 777A
Vionnet, N.; Gut, I.; Matsuda, F.; Marre, M.; Hadjadj, S.; Parving, H.H.; Tarnow, L.; Groop, P.H.; Forsblom, C.; Gauguier, D.; Cox, R.; Kazeem, G.; Farrall, M.; Lathrop, M.; Cambien, F. 2003: EURAGEDIC; European consortium for the genetics of diabetic nephropathy Strategy and first results. Diabetologia 46(Suppl 2): A55
Tomson, T.; Battino, D.; Beaussart, M.; Bonizzoni, E.; Craig, J.; Lindhout, D.; Perucca, E.; Vajda, F. 2001: EURAP An international pregnancy registry for the evaluation of the comparative teratogenic effects of antiepileptic drugs. Epilepsia 42(Suppl 7): 293
Humpal, D.; Owusu, E. 2003: EUREPGAP, worker safety and food safety in the Ghanaian pineapple industry. HortScience 38(5): 832
Licheri, D.; Scotti, A.; Spina, F. 2003: EURING Protocol Engine hosted by Ozzano Ringing Centre. Vogelwarte 42(1-2): 161
Folino Gallo, P.; Walley, T.; Frolich, J.C.; Carvajal, A.; Edwards, I.R.; Calamo Specchia, F.P. 2000: EURO-Medicines An analysis of the pharmaceutical policies in the European union. Pharmacoepidemiology and Drug Safety 9(Suppl 1): S53
Euroaspire II 2001: EUROASPIRE II Effect of cardiac rehabilitation programme on lifestyle and risk factor management and use of drug therapies in patients with coronary heart disease in fifteen European countries. European Heart Journal 22(Abstract Suppl): 493
Euroaspire Steering Group 2001: EUROASPIRE II Principal results of a European survey on secondary prevention of coronary heart disease. Circulation 104(17): 2; 792
Blazer, D. 1999: EURODEP Consortium and late-life depression. British Journal of Psychiatry: the Journal of Mental Science 174: 284-285
Valentini, R. 2003: EUROFLUX An integrated network for studying the long-term responses of biospheric exchanges of carbon, water, and energy of European forests. Valentini, Riccardo , Reprint Author Fluxes of carbon water and energy of European forests: 1-8
Aebi, M.; Berger, E.G.; Briones, P.; Von Figura, K.; Hennet, T.; Jaeken, J.; Korner, C.; Matthijs, G.; Van Schaftingen, E.; Vilaseca, M.A.; Wevers, R.; Winchester, B. 2002: EUROGLYCAN A systematic approach towards the understanding, diagnosis and treatment of CDG, a novel group of inborn metabolic disorders caused by defects of glycosylation. American Journal of Human Genetics 71(4 Suppl): 424
Ahsberg, E.; Iregren, A. 2000: EUROQUEST The structure of a new symptoms questionnaire. Neurotoxicology (Little Rock) 21(5): 881-882
Sigal, R.; Caramella, D.; Kurdziel, J.C.; Gandon, Y.; Lemort, M.; Salcito, G.; Frija, G.; Ringertz, H.; Baert, A.; Passariello, R. 1999: EURORAD, the EAR database project. Lemke, H U, Vannier, M W, Inamura, K, Farman, A G International Congress Series; Computer assisted radiology and surgery 312-317
Association, O.European Toxicologists 2000: Eurotox 2000. Toxicology Letters (Shannon) 116(Suppl 1): 67-118, September 1st
Pollack, B.J.; Kessler, S.; Birk, J.; Anderson, J.C. 2000: EUS assisted endoscopic removal of a large Brunners gland adenoma. American Journal of Gastroenterology 95(9): 2597-2598